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Cancer progression is characterized by the formation of tumors in primary organs and the 
subsequent re-formation of tumors in distant metastatic sites. The tumorigenic, or tumor-
forming, capacity of cancer cells drives cancer along a continuum that includes primary 
tumor formation, metastatic re-initiation, and macroscopic relapse. As such, a greater 
understanding of the biological features and molecular determinants that govern tumor-
forming capacity in the primary and metastatic site is of great importance to the scientific 
and biomedical communities. This thesis presents an unbiased approach to systematically 
select and characterize breast cancer cells with enhanced tumorigenic capacity in order to 
elucidate genes and cell biological features that are important to tumor-forming potential 
in primary and metastatic sites. 
The first part of this thesis describes a method to select for populations of cells with 
enhanced tumor-forming capacity from heterogeneous breast cancer populations. Two 
human Estrogen Receptor-negative (ER-negative) breast cancer cell lines, MDA-231 and 
CN34, were subjected to in vivo selection to yield ‘tumorigenic-enriched’ (TE) 
derivatives, which demonstrated enhanced tumor re-initiation capacity in multiple organ 
sites in a xenograft model. In the second part of this study, a systematic approach was 
employed to identify genes that promote tumor re-initiation. Transcriptomic profiling 
revealed a set of genes–LAMA4, FOXQ1, and NAP1L3–that were expressed at greater 
levels in tumorigenic-enriched derivatives relative to their parental populations. These 
genes were also expressed at greater levels in independently derived metastatic 
populations. All three of these genes were found to promote metastatic efficiency, and 
one of these genes, LAMA4, was subjected to further characterization. Functional studies 
revealed LAMA4 to promote clonal expansion during substratum-detachment in vitro, 
tumor re-initiation in multiple organ microenvironments, the proliferation of 
disseminated metastatic cells, and the formation of incipient micro-metastatic colonies in 
vivo. 
The final phase of this study revealed the association of LAMA4 expression with human 
breast cancer progression and clinical outcome in multiple patient datasets. In support of 
the role of LAMA4 in promoting early tumor formation, malignant breast cancer cells 
isolated from incipient breast cancer lesions were found to express higher levels of 
LAMA4 relative to pre-malignant cells from matched patient lesions. In addition, 
consistent with functional studies demonstrating the role of LAMA4 in driving primary 
and metastatic tumor re-initiation, higher levels of LAMA4 expression in ER-negative 
primary tumors correlated with worse relapse-free survival in multiple patient clinical 
cohorts.  
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CHAPTER I: INTRODUCTION 
 
Breast cancer: prevalence and prognosis 
Breast cancer leads all other female cancers in the numbers of annual diagnoses and 
deaths incurred globally (Jemal et al., 2011). Without intervention, almost all breast 
cancers will follow a common progression path through pre-malignant, malignant, and 
metastatic stages (Espina and Liotta, 2011). Transition through each of these stages is 
thought to be intricately linked to the capacity of cancer cells to initiate colonies and give 
rise to tumors (Magee et al., 2012). Although pre-malignant breast cancers have a low 
risk of mortality, they are often excised because a portion of them will eventually 
transition to malignant cancers, which have the ability to spread into the surrounding 
breast tissue (Leonard and Swain, 2004). Localized pre-malignant or malignant breast 
cancers have a median 5-year survival time upwards of 95% (Jemal et al., 2010), but 
malignant breast cancers are treated more aggressively due to their risk of metastatic 
dissemination. The 5-year survival for patients with metastatic breast cancer, disease that 
has spread from the primary site to a distal organ, is less than 25% (Jemal et al., 2010). 
Unfortunately, patients that have undergone treatment at any stage of breast cancer are at 
risk for relapse of either primary or metastatic disease (Hedley and Chambers, 2009). 
Such relapse is often the result of the re-formation of tumors from small residual numbers 
of breast cancer cells that have escaped treatment (Chaffer and Weinberg, 2011). An 
understanding of the features that enable cancer cells to form tumors and to re-initiate 
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tumors in distal organs could lead to more effective therapeutic intervention at multiple 
stages of cancer progression. 
Breast cancer: origins and progression 
Pathophysiology 
Breast cancer arises from the mammary gland, an organ residing in the breast that is 
surrounded by fat and connective tissue (Thomas, 2011). The mammary gland is 
comprised of a branching network of ducts and lobules lined with a bi-layered epithelium 
(Illustration 1.1) (Gusterson, 2009). The inner layer of the mammary ducts are lined by 
luminal cells, while the outer layer is lined by basal cells that are in direct contact with 
the basement membrane (BM) (Vargo-Gogola and Rosen, 2007). The basement 
membrane, composed of extracellular matrix (ECM) proteins, functions to provide cells 
with anchorage and important instructive proliferative and survival cues (Ghajar and 
Bissell, 2008). Interaction of normal and neoplastic mammary epithelial cells with the 
BM and other ECM components plays important roles in mammary gland homeostasis 





Illustration 1.1: The mammary gland 
The mammary gland is a branching organ comprised of ducts and lobules lined with a bi-
layered epithelium. The inner layer of the mammary ducts are lined by luminal cells, 
while the outer layer is lined by basal cells that are in direct contact with the basement 
membrane (BM). BM is basement membrane. 
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Mammary gland homeostasis is characterized by the expansion and involution of the 
mammary branches during development and the female reproductive life cycle (Ghajar 
and Bissell, 2008; Llobet-Navas et al., 2014). Deregulated homeostasis within the 
mammary gland can result in breast cancer, which is the unconstrained proliferation of 
oncogenically transformed mammary epithelial cells (Ercan et al., 2011). The oncogenic 
transformation of epithelial cells is the result of genetic and epigenetic alterations that 
lead to the acquisition of aberrant cell biological features that conflict with normal 
homeostatic control (Hanahan and Weinberg, 2000). These alterations enable cells to 
proliferate uncontrollably independent of extrinsic growth signals, evade normal 
safeguards that would lead to programmed cell death, and survive or become dormant in 
hostile external conditions, in addition to many other features (Hanahan and Weinberg, 
2000; Hedley and Chambers, 2009). Further genetic or epigenetic changes in neoplastic 
cells drives cancer progression along a continuum, broadly demarcated into the pre-
malignant, malignant, and metastatic stages. 
 
Pre-malignant and malignant breast cancer 
Upon oncogenic transformation of mammary epithelial cells, early breast cancer 
progression follows two distinct stages: the pre-malignant stage and the malignant stage 
(Illustration 1.2). Pre-malignant breast cancer is characterized by the proliferation and 
expansion of neoplastic cells into the mammary ducts without evidence of their 
penetration through the encapsulating basement membrane (Schatten, 2013). Based on 
their expansion but confinement to within the mammary ducts, pre-malignant breast 
cancers are also referred to as ductal carcinoma in situ (DCIS) (Espina and Liotta, 2011). 
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While pre-malignant cancer cells demonstrate many hallmarks of transformed cells, the 
benign nature of pre-malignant lesions is due to their confinement within the mammary 
gland and lack of escape into the surrounding stromal compartment (Chaffer and 
Weinberg, 2011). The confinement of pre-malignant lesions by the BM prevents them 
from growing to a large size, infiltrating into the surrounding tissue, and spreading to 
sites outside of the primary site (Talmadge and Fidler, 2010). The penetration of breast 
cancer cells through the BM and out of the mammary epithelium defines the transition 
from the pre-malignant stage to the malignant stage, and the biological factors that 
regulate progression to this stage remain largely unknown (Polyak, 2010). 
 
Malignant breast cancers are defined by evidence of cancer cell penetration through the 
BM of the mammary epithelium and into the surrounding stromal tissue. Due to their 
invasion out of the ducts and into the stromal compartment, malignant breast cancers are 
also referred to as invasive ductal carcinomas (IDC) (Ali and Coombes, 2002). Exit of 
cancer cells through the BM and into the stromal compartment reflects both their capacity 
to break down and invade through this barrier and to proliferate and survive without 
proper engagement to extracellular matrix proteins that are present outside of the 
mammary gland (Pavlova et al., 2013; Wan et al., 2013). An understanding of the 
molecular differences between pre-malignant and malignant cancer cells could lead to the 





Illustration 1.2: Pre-malignant and malignant breast cancer 
Pre-malignant breast cancer, also known as ductal carcinoma in situ (DCIS) is the 
precursor lesion to malignant breast cancer, also known as invasive ductal carcinoma 
(IDC). Pre-malignant breast cancer cells are confined within the basement membrane 
(BM) surrounding the mammary epithelium. The transition from pre-malignant to 
malignant breast cancer occurs once cancer cells have broken down and invaded through 
the BM and into the surrounding stromal micro-environment. 
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Primary tumor formation 
The penetration of malignant breast cancer cells through the basement membrane enables 
them to expand further and to develop into tumors of a substantial size (Talmadge and 
Fidler, 2010). The hallmarks of primary tumors include their large size, infiltration into 
the surrounding tissue, and capacity to enable vascularization to supply them with 
adequate nutrients and oxygen through the recruitment of vessel-forming endothelial cells 
(Folkman, 2002; Talmadge and Fidler, 2010). Cancer cells within primary tumors can 
also co-opt cells from the surrounding microenvironment, including fibroblasts, 
endothelial cells, and hematopoietic cells to induce them to produce important growth 
signals that further promote tumor maintenance and progression (Hanahan and Weinberg, 
2000). The capacity of cancer cells originating from malignant tumors to expand and 
invade into the surrounding tissue is one feature that predisposes them to spread to further 
distant sites and to re-initiate tumors in a metastatic organ (Talmadge and Fidler, 2010). 
 
The metastatic cascade 
The major cause of death in patients with breast cancer is metastasis, which involves the 
systemic spread of cancer cells and subsequent re-formation of tumors at distant organ 
sites (Hedley and Chambers, 2009). This process involves a cascade of several rate-
limiting steps, all of which must be completed in order for a successful metastatic event 
to occur (Illustration 1.3). The execution of this complex series of events in concert 
makes metastasis highly inefficient and a significant bottleneck in the progression of 
cancer (Langley and Fidler, 2011). 
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The first step of the metastatic cascade involves the detachment of cancer cells from the 
primary tumor and their entrance into the circulatory or lymphatic system. The entrance 
of cancer cells into the blood or lymphatics, known as intravasation, requires cancer cells 
to invade through the endothelial or smooth muscle layers that surround the lumen of 
vessels (Chaffer and Weinberg, 2011). Because intravasation can only occur if cancer 
cells have first invaded through the basement membrane and into the stromal 
compartment, only malignant breast cancers are thought to be able to metastasize (Ali 
and Coombes, 2002). Once inside the lymphatics or blood vessels, cancer cells gain 
access to a conduit from which they can access every organ in the body. 
 
The hematogenous or lymphatic dissemination of cancer cells exposes them to multiple 
barriers that must be overcome in order for them to survive (Mehlen and Puisieux, 2006). 
While in the circulation or lymphatics, cancer cells lack their previous attachment to 
important ECM components and nearby cells (Simpson et al., 2008), are targets of 
engulfment by phagocytic macrophages (Wan et al., 2013), and can become mechanically 
destroyed due by tortuous or small vessels (Wirtz et al., 2011). All of these features 
represent potential activators of programmed cell death that must be overcome by cancer 
cells. Although it is unknown how long cancer cells can survive before progressing to the 
next step along the metastatic cascade, circulating cancer cells have been reproducibly 




Metastatic progression of disseminated cancer cells continues through the re-entrance of 
cancer cells into distant organs and out of the circulation, a process known as 
extravasation. Extravasation occurs after the lodging, or embolization, of cancer cells in 
the endothelial linings of ectopic organs (Wirtz et al., 2011). In addition to physical 
lodging, cancer cell binding to endothelial cells through receptor-ligand interactions is 
thought to be required for their extravasation out of the circulatory system and back into 
the parenchyma of distant organs (Wirtz et al., 2011). However, different organs may 
have distinct requirements for extravasation that vary as a result of organ-specific 
features of the local vasculature. For example, the lungs are lined with an endothelial 
barrier that is highly restrictive to extravasation (Padua et al., 2008; Reymond et al., 
2013), while the sinusoidal endothelium of the liver is more permissive to cell seeding 
(Nguyen et al., 2009a). It is thought that these different requirements for extravasation 
may contribute to organ-selectivity by metastatic cells (Wirtz et al., 2011). 
 
The final rate-limiting step of the metastatic cascade, tumor re-initiation, occurs once 
cancer cells have extravasated and arrived in the parenchyma of a distal organ. During 
this stage, cancer cells arrive in an ectopic organ microenvironment that often lacks 
important proliferative and survival signals that would enable the formation of colonies 
(Fidler, 2003, 2011; Giancotti, 2013). The absence of cues from the ECM can lead to cell 
cycle arrest or a protracted period of cellular dormancy, whose length can vary from only 
a short period of time to up to several years (Wan et al., 2013). In order to re-initiate a 
tumor, a small number of cancer cells (or potentially only one cancer cell) must regain 
proliferative capacity and re-initiate a new colony in this non-permissive context. It is 
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thought that remodeling of the local microenvironment through the secretion or 
modulation of extracellular proteins contributes to the re-activation of disseminated 
cancer cells (Wan et al., 2013). The capacity of limiting numbers of cancer cells to 
overcome this final barrier through largely unknown mechanisms is the gateway to 
metastatic tumor re-initiation.  
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Illustration 1.3: The metastatic cascade 
The metastatic cascade is a series of complex rate-limiting steps that all must be 
completed by cancer cells in order for a successful metastatic event to occur. Some of 
these steps include detachment from the primary tumor site, intravasation into the 
circulation or lymphatics, dissemination, extravasation of cancer cells out of the 
circulation and into the tissue of an ectopic organ, and the re-initiation of metastatic 
tumors. 
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Primary and Metastatic Relapse 
While many treatments for breast cancer can reduce tumor burden to undetectable levels, 
even the most effective treatments are limited in their ability to completely eliminate 
every cancer cell (Chaffer and Weinberg, 2011). As a result, it is thought that the capacity 
of cancer cells to re-initiate tumors from small numbers of residual cells exposes almost 
all breast cancer therapies to an inherent risk of relapse (Hu et al., 2013). Breast cancer 
relapse can occur at either at the primary or a metastatic site regardless of the stage of the 
patient at the time of therapy (Hedley and Chambers, 2009). For example, a patient 
treated for localized primary breast cancer can succumb to metastatic relapse in the lung 
years after her initial treatment due to the presence of a small numbers of cells escaping 
therapy and re-initiating tumors at a later time (Hedley and Chambers, 2009). The factors 
contributing to the latency observed in relapse are generally unknown, but they are 
thought to reflect the potential of cancer cells to remain dormant and resistant to therapy 
for a protracted period of time (Wan et al., 2013). Xenograft models that assess the 
capacity of cancer cells to propagate, or re-initiate, tumor growth in primary or metastatic 
sites model this process by mimicking the physiological formation of tumors from small 
numbers of cells (Magee et al., 2012). 
 
Breast cancer: therapeutic intervention 
Breast cancer therapy is diverse in part due to the biological heterogeneity of this disease 
(Byler et al., 2014). Many subtypes of breast cancer exist with distinct clinical behavior, 
and these subtypes can be distinguished based on morphology or molecular analysis 
(Gusterson, 2009; Schatten, 2013). Breast cancer subtypes can broadly be distinguished 
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into two groups based on their expression of the estrogen hormone receptor (Putti et al., 
2005). Estrogen Receptor-positive (ER-positive) breast cancers are often dependent on 
estrogen for their growth, maintenance, and progression (Kim et al., 2012). Estrogen 
Receptor-negative (ER-negative) breast cancers are generally more aggressive and 
metastasize more frequently than ER-positive cancers (Putti et al., 2005; Thomas and 
Gustafsson, 2011). In addition to being less aggressive, the hormone-dependence of ER-
positive tumors can be exploited therapeutically through targeting with anti-estrogen 
therapy (Andre and Pusztai, 2006). Anti-hormone therapies such as tamoxifen have led to 
a significant decrease in the number of deaths incurred by ER-positive breast cancer and 
greatly improved the management of this disease (Brisken, 2013; Powles, 2002). In 
contrast, targeted therapies for ER-negative disease (which represent approximately 30% 
of all breast cancers (Zhang et al., 2011b)) are limited (Putti et al., 2005). An 
understanding of the biological mediators that drive ER-negative breast cancer has the 
potential to reveal novel targets for therapeutic intervention and is of great interest to the 
biomedical research community. 
 
Breast cancer: experimental models 
Tumor re-initiation 
The tumor-forming capacity of cancer cells can be experimentally modeled with 
xenograft ‘tumor re-initiation assays,’ which assess the potential of human cancer cells to 
re-initiate macroscopic tumors in a secondary host upon implantation into a particular 
organ (such as the mammary gland of a mouse) (Williams et al., 2013). Tumor re-
initiation assays physiologically mimic the formation of tumors from small numbers of 
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cells, which occurs during primary tumor formation, metastatic re-initiation, and relapse. 
It is thought that the capacity of cancer cells to give rise to tumors in a xenograft model is 
reflective of features important to each of these processes (O'Brien et al., 2010). 
 
The identification and characterization of cancer populations with tumorigenic potential 
in xenograft models has been subject to numerous scientific investigations (Nguyen et al., 
2012; O'Brien et al., 2010). The tumor-forming potential of human cancer cells can vary 
tremendously in such models, with studies reporting tumors being formed from just one 
cell to upwards of hundreds of thousands of cells (Ishizawa et al., 2010; Quintana et al., 
2008). This variability has been attributed to the type of cancer studied, the xenograft 
model used, or whether the source was a primary tumor, metastatic lesion, or cell line 
(Buchstaller et al., 2012; Quintana et al., 2008). Even different sub-populations of cancer 
cells derived from the same tumor source may have substantial variability in their 
tumorigenic capacity (Al-Hajj et al., 2003; Prince et al., 2007). For example, several 
investigators have employed cell surface markers to prospectively isolate different sub-
populations of cells that are then subject to phenotypic assays to determine their 
tumorigenic potential (Chaffer et al., 2013; Cordenonsi et al., 2011; De Vito et al., 2012; 
He et al., 2013; Shimono et al., 2009; Vermeulen et al., 2010; Visvader and Lindeman, 
2012). While many of these studies have been greatly informative, most rely on the use 
of one or multiple markers to sort different populations of cells and then separately test 
their tumorigenic potential (Owens and Naylor, 2013). The discovery of important 
biological mediators of tumor-forming capacity could be aided through the development 
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of an alternative systematic approach to select and characterize breast cancer populations 
with enhanced tumorigenicity. 
 
While characterization of mediators of tumorigenic capacity has important consequences 
for the understanding of primary disease, whether the primary tumor-forming potential of 
cancer cells is sufficient to also enable the propagation of tumors at distant sites during 
metastatic progression is also a question of considerable interest (Magee et al., 2012). 
While tumor-forming potential in the primary and metastatic site appear to share some 
similarities, the molecular features common to highly tumorigenic cells and metastatic 
cells has not been systematically studied (Magee et al., 2012; Vanharanta and Massague, 
2013), and further characterization of both of these processes remains an area of active 
investigation (Chakrabarti et al., 2012; Korpal et al., 2011; Piao et al., 2014). 
 
Experimental metastasis 
Multiple steps of the metastatic cascade can be examined experimentally using mouse 
xenograft models. The most complete xenograft models of breast cancer metastasis allow 
metastasis to occur in a mouse following the orthotopic implantation of primary tumors 
into the mammary gland (Hedley and Chambers, 2009). Cancer cells that metastasize to 
distant organs from this context must complete all steps of the metastatic cascade, 
including intravasation from the primary site, dissemination into the circulation, 
extravasation into distal organs, and the eventual re-initiation of tumors (Khanna and 
Hunter, 2005). While they have the advantage of encompassing all steps of the metastatic 
cascade, orthotopic models of metastasis are limited in their ability to draw conclusions 
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about specific steps (Khanna and Hunter, 2005). Specific stages of the metastatic cascade 
can be studied by introducing cancer cells into mice along particular stages of interest. 
For example, intravasation can be quantified by measuring the numbers of cancer cells 
that have disseminated into the circulation from a primary tumor implant (Gupta et al., 
2007). Metastatic extravasation and colonization can be studied by injecting cells into the 
venous circulation of mice and evaluating the numbers of cells that have entered a 
metastatic organ and the numbers of colonies formed, respectively (Khanna and Hunter, 
2005). While many of these experimental assays have been conducted and have yielded 
important insights into the underling biology of multiple steps of the metastatic cascade, 
sufficient understanding of metastatic re-initiation, the final step of the metastatic cascade, 
is still lacking. 
 
In vivo selection 
In vivo selection is an experimental technique that can be used to select for populations 
enriched for a particular phenotype of interest. Populations with enhanced fitness for 
malignant phenotypes have been derived from heterogeneous cancer populations using 
this method (Fidler, 2003). Several investigators have employed in vivo selection of 
human cancer populations to enrich for cancer cells that demonstrate enhanced metastatic 
capacity relative to their parental populations in xenograft models of experimental 
metastasis (Clark et al., 2000; Fidler, 1973; Gumireddy et al., 2009; Gumireddy et al., 
2007; Kang et al., 2003; Minn et al., 2005; Pencheva et al., 2012; Tavazoie et al., 2008; 
Xu et al., 2008). Comparison of such highly metastatic derivatives to their parental 
populations has led to the identification of functional molecular regulators of metastasis 
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with prognostic and therapeutic significance in multiple human cancers (Clark et al., 
2000; Gumireddy et al., 2009; Gupta et al., 2007; Kang et al., 2003; Nguyen et al., 2009b; 
Pencheva et al., 2012; Png et al., 2012; Tavazoie et al., 2008; Zhang et al., 2013a). 
 
In the study of breast cancer metastasis, two breast cancer cell lines, MDA-MB-231 
(Cailleau et al., 1978) and CN34 (Gomis et al., 2006), were previously subjected to in 
vivo selection to generate the lung-metastatic (LM) derivative populations MDA-LM2 
(Minn et al., 2005) and CN34-LM1a (Tavazoie et al., 2008), respectively. These 
populations were selected for their capacity to colonize the lungs upon intravenous 
inoculation into immunodeficient mice, and both the MDA-LM2 and CN34-LM1a 
demonstrate robust capacity to metastasize to the lungs in xenograft models (Png et al., 
2012; Tavazoie et al., 2008). Systematic molecular characterization of LM populations 
has led to the identification of molecular regulators of specific features of the metastatic 
process, including cell invasion (Tavazoie et al., 2008), endothelial recruitment (Png et 
al., 2012), and trans-endothelial migration (Padua et al., 2008). Molecular regulators 
identified using this approach include the microRNAs miR-335 and miR-126 (Tavazoie 
et al., 2008), which suppress metastasis by repressing the expression of the effector genes 
SOX4, and TNC (in the case of miR-335) (Tavazoie et al., 2008) and IGFBP2, MERTK 
and PITPNC1 in the case of (miR-126) (Png et al., 2012). 
 
While important regulators of sequential steps of the metastatic cascade have been 
identified employing in vivo selection for metastasis, due to selection for this multi-step 
phenotype, characterizing the molecular basis of a specific step a priori, such as tumor 
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re-initiation, remains challenging. The identification of the molecular determinants that 
mediate tumor re-initiation in both the primary and metastatic settings could further 
advance the understanding of both of these processes. 
 
Specific aims 
The goal of this thesis is to contribute to the understanding of the cellular and molecular 
properties that enable small number of cancer cells to form tumors in the primary or 
metastatic microenvironment. The first phase of this study describes the development of a 
system to select and characterize cells with enhanced tumorigenic capacity in a xenograft 
model. Populations of breast cancer cells with enhanced tumorigenic capacity were 
derived through the application of selective pressure for tumor formation from low cell 
numbers (Chapter II). These tumorigenic-enriched populations were extensively 
characterized and found to give rise to xenograft tumors at greater frequency in multiple 
organ microenvironments. 
 
The second phase of this study applied a systematic approach to identify genes that 
promote tumor re-initiation and to uncover the cell biology governed by these genes 
(Chapter III). Three genes were identified– LAMA4, FOXQ1, and NAP1L3–to be 
expressed at greater levels by highly tumorigenic and highly metastatic cells and one of 
these genes LAMA4, was selected for further study. Functional characterization of 
LAMA4 revealed it to promote tumor re-initiation in multiple microenvironments, clonal 
expansion of cancer cells in the absence of substratum attachment in vitro, and 
disseminated metastatic proliferation and colony formation. 
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The third phase of this study presents clinical evidence to support the significance of 
these findings to human breast cancer progression (Chapter IV). Multiple datasets 
revealed that increased expression of LAMA4 marked the transition from pre-malignant to 
malignant breast cancer, and revealed that higher expression of LAMA4 in ER-negative 
tumors was associated with poor relapse-free survival. Further discussion of the major 




SELECTION AND CHARACTERIZATION OF BREAST CANCER 
CELLS WITH ENHANCED TUMORIGENIC CAPACITY 
 
The primary goal of this study is to better understand the biology through which small 
numbers of cancer cells give rise to tumors. As the first step to identify cellular and 
molecular determinants associated with this process, this chapter describes the 
development of an experimental system to select and characterize cancer cells with 
enhanced tumorigenic capacity. 
 
In vivo selection for tumor re-initiation yields tumorigenic-enriched (TE) derivatives 
In order to study the biology that governs breast cancer tumor re-initiation, in vivo 
selection was used to derive populations of human breast cancer cells with enhanced 
tumor-forming capacity. Independent human breast cancer cell lines, the established 
MDA-MB-231 (MDA-231) line (Cailleau et al., 1978; Minn et al., 2005) and the 
minimally passaged CN34 line (Tavazoie et al., 2008), were subjected to in vivo 
selection. These cell lines were selected for study in part due to their Estrogen Receptor-
negative (ER-negative) status (Bos et al., 2009). ER-negative breast cancers are generally 
more aggressive and have fewer therapeutic options relative to ER-positive breast cancers 
(Putti et al., 2005). Selective pressure for tumor re-initiation was applied to the MDA-231 
and CN34 cell lines by injecting increasingly limiting numbers of these populations 
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orthotopically into the mammary fat pads of immunodeficient mice in order to generate 





Figure 2.1: In vivo selection for tumor re-initiation 
Schematic of the strategy of in vivo selection used to derive populations with enhanced 
tumorigenic potential. Breast cancer cells were injected into the mammary fat pads of 
immunodeficient mice at low cell numbers and the resulting tumors formed were 




During the first round of in vivo selection for tumor re-initiaiton, both the MDA-231 and 
CN34 cell lines gave rise to tumors at non-saturating (less than 100-percent) frequency at 
the initial cell doses used (10,000 or 20,000 cells, for the MDA-231 or CN34 cell lines, 
respectively) upon injection into the mammary fat pads of immunodeficient mice (Figure 
2.2). The non-saturating frequency of tumor re-initiation suggested that selective pressure 
for tumor formation existed at this dose. 
 
Tumors that were formed during this first round of in vivo selection were dissociated to 
yield 1st-generation MDA-231 and CN34 tumorigenic-enriched (TE) derivatives MDA-
TE1 and CN34-TE1, which were expanded and propagated in vitro. A second round of in 
vivo selection was conducted by re-injecting these 1st-generation derivatives at a 10-fold 
lower dose (1,000 or 2,000 cells, for MDA-TE1 and CN34-TE1, respectively) and 
dissociating the resulting tumors to yield 2nd-generation TE derivatives MDA-TE2 and 
CN34-TE2 (Figure 2.2). Notably, during the second round of in vivo selection, the 
frequency of tumors formed by the TE1 derivatives was greater than the initial frequency 
demonstrated  by the parental  populations  (15/20 vs. 9/20 and 20/20 vs. 8/20  for  the 
MDA-231 or CN34 cell lines, respectively) even though 10-fold fewer cells were injected 
(Figure 2.2). These initial results suggested that enrichment for tumor-forming capacity 
had occurred after only one round of in vivo selection. For the MDA-231 cell line, a third 
round of in vivo selection was performed to generate the MDA-TE3 derivative 
population, while the CN34 cell line only underwent two rounds of in vivo selection to 
generate the CN34-TE2 derivative population. Subsequent experiments focused on 





Figure 2.2: Selection for multiple tumorigenic-enriched (TE) derivative populations 
Flow chart depicting the generation of tumorigenic-enriched (TE) derivatives from the 
MDA-MB-231 (MDA-231) and CN34 parental cell lines (left). Table depicting the 
number of injected cells and the numbers of tumors formed per mammary fat pad 
injection into immunodeficient NOD scid mice during the process of generating the in 
vivo selected derivatives (right).  
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Tumorigenic-enriched (TE) derivatives demonstrate enhanced orthotopic tumor re-
initiation capacity relative to their parental populations 
Functional experiments revealed that tumorigenic-enriched derivatives MDA-TE3 and 
CN34-TE2 gave rise to xenograft tumors at significantly greater frequency (up to 12-
fold) when injected into the mammary fat pads of immunodeficient mice at low cell 
numbers (100 or 2,000 cells, for the MDA-231 or CN34 cell lines, respectively) relative 
to their respective parental populations (Figure 2.3a-b). These results demonstrate that 
populations of cells with significantly enhanced tumor re-initiation capacity can be 
derived from human breast cancer populations through in vivo selection. 
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Figure 2.3: Tumorigenic-enriched (TE) derivatives demonstrate enhanced tumor re-
initiation capacity 
(a) MDA-TE3 cells exhibited enrichment for tumor re-initiation capacity as compared to 
MDA-parental cells following orthotopic injection of 1x102 cancer cells into NOD scid 
mice. MDA-TE3 cells yielded tumors in 12/20 sites compared to 1/20 sites for the MDA-
parental cells after 10 weeks (left). Gross tumor explants (right). n = 20 independent 
mammary fat pad injections (represented as open squares, right). (b) CN34-TE2 cells 
exhibited enrichment for tumor re-initiation capacity as compared to CN34-parental cells 
following orthotopic injection of 2x103 cancer cells into NOD scid gamma mice. CN34-
TE2 cells yielded tumors in 19/20 sites compared to 12/20 sites for the CN34-parental 
cells after 10 weeks (left). Gross tumor explants (right). n = 20 independent mammary fat 
pad injections (represented as open squares, right). **P<0.01, ***P<0.001 were obtained 
using one-sided Fisher’s exact test (a-b). 
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Tumorigenic-enriched (TE) derivatives robustly colonize multiple organs relative to 
their parental populations 
A fundamental question of great interest in cancer biology is the relationship between 
primary tumor-forming potential and metastatic activity, (Diehn and Majeti, 2010; Magee 
et al., 2012; Rhim et al., 2012; Song et al., 2013). Highly tumorigenic cells have been 
posited to be more able to metastasize (Brabletz et al., 2005), while other studies have 
suggested these processes to be independent (Brabletz, 2012; Visvader and Lindeman, 
2012). As an important first step to address this issue, the capacity of tumorigenic-
enriched derivatives to re-initiate tumors in an ectopic metastatic site was assessed. When 
injected directly into the lung parenchyma, TE derivatives gave rise to a greater number 
of macroscopic tumors in the lungs relative to their respective parental populations 
(Figure 2.4a-d), demonstrating that they were enriched in ectopic tumor re-initiation 
capacity in addition to orthotopic tumor re-initiation capacity. 
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Figure 2.4: Tumorigenic-enriched cells demonstrate enhanced ectopic tumor re-
initiation capacity relative to their parental populations 
(a-b) 1x103 MDA-parental or MDA-TE3 cells were injected directly into the lung 
parenchyma to assess ectopic tumor re-initiation capacity. Lung bioluminescence was 
measured on day 53 and normalized to post-injection signal at day 0 (a). n = 7 
independent mice. On day 53 lungs were sectioned, vimentin stained, and the number of 
macroscopic nodules per lung was counted (b). n = 3 independent lungs. (c-d) 1x105 
CN34-parental or CN34-TE2 cells were injected directly into the lung parenchyma to 
assess ectopic tumor re-initiation capacity. Lung bioluminescence was measured on day 
56 and normalized to post-injection signal at day 0 (c). On day 56 lungs were sectioned, 
vimentin stained, and the number of macroscopic nodules per lung was counted (d). n = 8 
(Parental), n = 9 (TE2) independent lungs. *P<0.05, **P<0.01, ***P<0.001 were 
obtained using a one-sided Mann-Whitney test (a, c) or a one-sided Student’s t-test (b, 
d). All data are represented as mean + S.E.M. 
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The enhanced ectopic tumor re-initiation capacity displayed by the TE derivatives 
suggested that these populations might also demonstrate enhanced colonization of organs 
during metastasis. Because organ-specific features such as the endothelial tight-junctions 
of the lungs represent significant barriers to cell extravasation (Padua et al., 2008; 
Reymond et al., 2013), TE derivatives would be expected to display an increased capacity 
to metastasize to an organ with less stringent requirements for trans-endothelial 
migration, whereby colonization is primarily driven by tumor-forming capacity. When 
TE cells were assessed for their capacity to metastasize to the liver–an organ whose 
fenestrated sinusoidal capillaries more readily permit cell seeding (Nguyen et al., 2009a)–
TE cells gave rise to a significantly greater number of macroscopic tumors in the liver 




Figure 2.5: Tumorigenic-enriched cells demonstrate enhanced liver metastasis 
relative to their parental populations 
(a-b) 1x105 MDA-parental or MDA-TE3 cells were injected into the portal circulation 
via splenic injection in order to assess metastasis to the liver. Liver colonization was 
measured by bioluminescence imaging at day 35 normalized to post-injection signal at 
day 0 (a). n = 5 independent mice. On day 35 livers were sectioned, H&E stained, and 
number of macroscopic nodules was counted (b). Arrows, representative nodules. n = 5 
independent livers. (c-d) 2x105 CN34-parental or CN34-TE2 cells were injected into the 
portal circulation via splenic injection in order to assess metastasis to the liver. Liver 
colonization was measured by bioluminescence imaging on day 56 and normalized to 
post-injection signal at day 0 (c). n = 4 independent mice. On day 56 livers were 
sectioned, H&E stained, and number of macroscopic nodules was counted (d). Arrows, 
representative nodules. n = 4 independent livers. *P<0.05, **P<0.01 were obtained using 
a one-sided Mann-Whitney test (a, c) or a one-sided Student’s t-test (b, d). All data are 
represented as mean + S.E.M.  
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Taken together, these results demonstrate that in vivo selection for orthotopic tumor re-
initiation is sufficient to co-select for enhanced colonization of multiple organs. The 
generation of multiple tumorigenic-enriched derivatives with enhanced tumorigenic 
capacity supports the use of this system to interrogate the cellular and molecular features 
important to this process. 
 
Characterization of tumorigenic-enriched derivatives 
Phenotypic differences between tumorigenic-enriched cells and their parental populations 
would be expected to reveal biology important to the process of tumor re-initiation. 
Experiments were conducted to compare TE derivatives with their parental populations 
across multiple in vitro phenotypes typically considered to confer a pro-tumorigenic 
advantage. Surprisingly, TE derivatives proliferated and formed colonies in vitro to a 
lesser extent than their parental populations upon standard adherent cell culture 
conditions (Figure 2.6a-d), did not demonstrate significant differences in their capacity to 
attach to tissue culture plates in vitro (Figure 2.6e-f), and did not recruit a greater number 
of endothelial cells relative to their parental populations in vitro (Figure 2.6g-h). These 
findings suggested that the enhanced in vivo tumor-forming capacity demonstrated by TE 
derivatives was independent of traditional in vitro phenotypes thought to be associated 
with enhanced tumorigenic potential. Additionally, immuno-phenotypic characterization 
of the MDA-TE3 or CN34-TE2 derivatives did not reveal enrichment of CD44+/CD24- 
markers relative to their respective parental populations (Figure 2.7a,b). The absence of 
enhancement of these multiple phenotypes in tumorigenic-enriched derivatives relative to 
their parental populations suggested that a molecular approach to systematically identify 
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differences between these cell populations might be more revealing of important 
determinants of tumor re-initiation in breast cancer.  
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Figure 2.6: In vitro characterization of tumorigenic-enriched derivatives 
(a) 2.5x104 MDA-parental or MDA-TE3 cells were seeded into 6-well adherent tissue-
culture plates. The number of cells per well on day 5 was counted and normalized to cell 
counts on day 1. n = 3 independent wells. (b) 2.5x104 CN34-parental or CN34-TE2 cells 
were seeded into 6-well adherent tissue-culture plates. The number of cells per well on 
day 5 was counted and normalized to cell counts on day 1. n = 3 independent wells. (c) 
1x102 MDA-parental or MDA-TE3 cells were seeded into 10cm adherent tissue-culture 
plates. The number of colonies per well on day 14 was counted upon staining with 
crystal-violet. n = 3 independent plates. (d) 1x102 CN34-parental or CN34-TE2 cells 
were seeded into 10cm adherent tissue-culture plates. The number of colonies per well on 
day 14 was counted upon staining with crystal-violet. n = 3 independent plates. (e) 
Assessment of cell attachment to adherent tissue culture plates of MDA-Parental cells 
compared to MDA-TE3 cells. n = 3 independent wells. (f) Assessment of cell attachment 
to adherent tissue culture plates of CN34-Parental cells compared to CN34-TE3 cells. n = 
6 independent wells. (g) Endothelial recruitment assay comparing the relative capacity of 
MDA-Parental cells and MDA-TE3 cells recruit Human Vein Endothelial Cells 
(HUVECs). n = 6 independent trans-well inserts. (h) Endothelial recruitment assay 
comparing the relative capacity of CN34-Parental cells and CN34-TE3 cells recruit 
Human Vein Endothelial Cells (HUVECs). n = 8 independent trans-well inserts.  NS is 
not significant. **P<0.01, ***P<0.001 were obtained using a two-sided student’s t-test 






Figure 2.7: Immuno-phenotypic characterization of tumorigenic-enriched 
derivatives 
(a) MDA-parental and MDA-TE3 populations were stained with antibodies specific to 
the cell surface markers CD44 and CD24 and analyzed using flow cytometry. For the 
MDA-parental population, 86.1% of the cells were CD44+CD24-. For the MDA-TE3 
population, 84.4% of the cells were CD44+CD24-. (b) CN34-parental and CN34-TE2 
populations were stained with antibodies specific to the cell surface markers CD44 and 
CD24 and analyzed using flow cytometry. For the CN34-parental population, 89.1% of 
the cells were CD44+CD24-. For the CN34-TE2 population, 86.1% of the cells were 
CD44+CD24-.   
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Summary of findings from Chapter II 
This chapter describes the selection and characterization of breast cancer populations 
with enhanced tumor-forming capacity. Two ER-negative breast cancer cell lines, MDA-
MB-231 and CN34, were subjected to in vivo selection for tumor re-initiation, leading to 
the generation of independent tumorigenic-enriched (TE) derivatives. Tumorigenic-
enriched derivatives were propagated and expanded in vitro, and gave rise to tumors at 
greater frequency relative to their parental populations when injected orthotopically into 
immunodeficient mice at low cell numbers. TE derivatives also demonstrated enhanced 
capacity to re-initiate tumors relative to their parental populations when introduced into 
multiple ectopic organs. These findings demonstrated that propagatable populations of 
cells with enhanced tumor re-initiation capacity can be derived from breast cancer cell 
lines using in vivo selection and that selection for tumor-forming potential in the primary 
site is sufficient to co-select for enhanced tumor re-initiation capacity in multiple ectopic 
organs. 
Tumorigenic-enriched derivatives were further characterized by subjecting them to 
multiple in vitro experimental assays thought to be associated with enhanced tumor-
forming capacity. Surprisingly, tumorigenic-enriched derivatives performed in these 
assays to the same or lesser extent relative to their parental populations, suggesting that 
the enhanced tumorigenic potential of TE populations was independent of features 
represented by these assays. The following chapter presents a systematic effort to identify 
molecular differences that could distinguish tumorigenic-enriched cells from their 
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parental populations in order to uncover potential molecular regulators of tumor re-




IDENTIFICATION OF MOLECULAR DETERMINANTS OF 
TUMOR RE-INITIATION 
 
This chapter describes a systematic approach to identify putative general promoters of 
tumor re-initiation through the molecular characterization of tumorigenic-enriched 
derivatives. Whole-genome transcriptomic profiling of tumorigenic-enriched and parental 
breast cancer populations was employed in order to identify candidate promoters of 
tumor re-initiation that function independent of the local microenvironment. This 
approach uncovered a set of genes expressed at greater levels by tumorigenic-enriched 
and metastatic derivative populations relative to their parental populations. One of these 
genes, LAMA4, was then extensively characterized. Further examination of LAMA4 
revealed it to promote tumor re-initiation in multiple organ microenvironments, clonal 
expansion in the absence of substratum attachment in vitro, and disseminated metastatic 
proliferation and colony formation in vivo. 
 
LAMA4, FOXQ1, and NAP1L3 display increased expression levels in tumorigenic-
enriched and metastatic cells relative to parental populations 
Upon generating tumorigenic-enriched (TE) derivatives with enhanced tumor-forming 
capacity relative to their parental populations, a systematic approach was used to identify 
candidate genes that might govern this process. Promoters of tumor re-initiation would be 
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expected to have greater expression levels in TE cells relative to their parental 
populations. Whole-genome transcriptomic profiling of TE derivatives from both the 
MDA-231 and CN34 cell lines revealed a large set of genes (169, Table 3.1) that 
displayed at least 1.5-fold greater expression in these cells relative to their respective 
parental populations (Figure 3.1b). This set of genes represented potential drivers of 
tumor re-initiation, promoters of selective growth in the mammary gland, as well as 
passenger genes lacking functional significance (Figure 3.1a).  
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Table 3.1: Genes with increased expression (1.5x higher) in tumorigenic-enriched 









TE2 FC* # 
BCHE 7.17 11.14 1 TGFBR2 1.96 1.90 86 
SLCO1B3 2.74 10.81 2 MAFF 1.76 2.08 87 
TIMP3 1.89 10.17 3 IL7 2.16 1.65 88 
BCHE 3.89 7.84 4 CD82 1.68 2.11 89 
ALOX5AP 1.85 8.27 5 TGFBR2 1.79 2.00 90 
PKIA 2.51 7.23 6 NAV3 1.52 2.25 91 
C13orf15 2.16 7.38 7 GPR37 1.73 2.04 92 
IL1A 2.67 6.75 8 STAT3 1.55 2.21 93 
IL1B 5.66 3.11 9 NAV2 1.72 2.02 94 
IGFBP1 1.97 6.52 10 CLDN7 1.96 1.77 95 
HOXB5 1.99 6.48 11 TMTC2 1.76 1.95 96 
TMEM163 2.18 5.86 12 HNMT 2.05 1.64 97 
LOC653506 1.93 5.93 13 FOXQ1 1.60 2.07 98 
PKIA 2.37 5.37 14 PUAEN2 1.67 1.99 99 
SLIT2 1.91 5.76 15 EMP1 1.94 1.71 100 
TMEM71 1.82 5.24 16 NFE2L3 1.79 1.86 101 
ADAMTS1 2.49 4.13 17 SH3BGRL 1.53 2.12 102 
IGFBP1 1.76 4.76 18 FRMD3 1.76 1.88 103 
NAP1L3 1.78 4.62 19 COG6 1.77 1.87 104 
CACNA2D4 3.60 2.72 20 CDKN1B 1.70 1.93 105 
KLF2 1.95 4.37 21 PCMTD1 1.98 1.65 106 
HIST1H1C 1.75 4.47 22 IRAK3 2.11 1.51 107 
HIST2H2AA3 1.85 4.34 23 PAN3 1.55 2.06 108 
LAMA4 1.81 4.39 24 GOLT1B 1.65 1.97 109 
KHDRBS3 1.75 4.34 25 COG3 1.82 1.78 110 
APOLD1 2.04 4.00 26 SLITRK5 2.06 1.54 111 
LOC100008589 3.52 2.51 27 RGS17 1.73 1.85 112 
METRNL 1.69 4.30 28 C11orf54 1.86 1.71 113 
INSIG1 2.78 3.17 29 RCN3 1.79 1.78 114 
BTG1 1.59 4.24 30 CR738291 1.56 2.00 115 
KYNU 3.93 1.83 31 NDFIP2 1.57 1.99 116 
GPC6 1.56 4.19 32 LOC442597 1.93 1.62 117 
RASD1 1.70 4.05 33 NAMPT 1.72 1.82 118 
HIST2H2AA3 1.66 4.07 34 ZMIZ2 1.60 1.93 119 
PTGS2 2.21 3.50 35 TM7SF3 1.59 1.93 120 
LMTK3 1.98 3.57 36 C13orf23 1.85 1.67 121 
CRADD 3.45 2.08 37 PITPNC1 1.55 1.96 122 
NSBP1 1.82 3.69 38 SATB2 1.75 1.76 123 
TMEM154 3.25 2.22 39 KIAA1024 1.58 1.92 124 
KHDRBS3 1.95 3.44 40 ARMCX3 1.53 1.96 125 
PRDM8 1.51 3.81 41 HNMT 1.95 1.54 126 
C21orf7 2.76 2.54 42 ERCC5 1.74 1.75 127 
TMEM154 3.08 2.21 43 FBXO33 1.56 1.93 128 
ARHGDIB 1.65 3.59 44 DDIT3 1.57 1.91 129 
PCDHB2 2.22 3.01 45 WDR51B 1.58 1.90 130 
*Fold-change (FC) reflective the expression of (tumorigenic-enriched derivatives)/(parental populations).
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TE2 FC* # 
ANTXR2 2.02 3.17 46 CCDC28A 1.76 1.72 131 
SRGN 3.54 1.63 47 TAF15 1.65 1.79 132 
SRGN 3.43 1.68 48 MBNL2 1.51 1.93 133 
ANKRD10 1.78 3.22 49 AP1S1 1.67 1.73 134 
SPRY1 2.45 2.49 50 MANSC1 1.73 1.66 135 
LOC730525 2.52 2.38 51 ICAM3 1.67 1.72 136 
SPRY1 2.44 2.43 52 MYCBP2 1.70 1.69 137 
PTPRR 2.24 2.61 53 KIAA0355 1.74 1.63 138 
C10orf90 1.66 3.12 54 LOC286467 1.79 1.56 139 
ID3 1.95 2.80 55 C12orf35 1.80 1.54 140 
ST6GAL1 2.54 2.19 56 GPR162 1.83 1.50 141 
DLG4 2.39 2.30 57 RAB38 1.70 1.60 142 
EREG 2.38 2.29 58 ESAM 1.57 1.73 143 
STAT5A 1.52 3.10 59 MANSC1 1.56 1.72 144 
DOCK10 2.16 2.43 60 C7orf46 1.67 1.58 145 
HDAC9 1.76 2.70 61 CKAP2 1.50 1.75 146 
ANKRD10 1.60 2.81 62 EAF1 1.61 1.64 147 
DYNC1I1 1.84 2.50 63 TGDS 1.63 1.61 148 
C4orf34 1.65 2.68 64 TM9SF2 1.59 1.65 149 
DUSP6 1.57 2.74 65 MBNL2 1.54 1.69 150 
MRIP 1.56 2.72 66 CBX5 1.71 1.52 151 
INSIG1 2.01 2.26 67 CARKD 1.66 1.56 152 
QPCT 2.47 1.79 68 PPM1F 1.62 1.60 153 
UFM1 1.81 2.39 69 ATF4 1.55 1.65 154 
ICAM2 1.75 2.44 70 GNG11 1.67 1.52 155 
VGLL4 1.87 2.29 71 ASB1 1.68 1.51 156 
KYNU 2.60 1.56 72 ANKDD1A 1.50 1.68 157 
CDK6 1.55 2.57 73 LOC285074 1.57 1.61 158 
TM4SF1 1.71 2.41 74 FLJ21986 1.53 1.65 159 
SEMA3A 2.20 1.89 75 ERRFI1 1.61 1.55 160 
MTSS1 1.78 2.29 76 MTIF3 1.55 1.60 161 
CDKN1B 1.65 2.41 77 JMJD1C 1.56 1.57 162 
UFM1 1.89 2.13 78 IER5L 1.56 1.56 163 
DUSP6 1.50 2.49 79 SERINC1 1.51 1.60 164 
SLCO4A1 2.03 1.93 80 SMARCC2 1.51 1.60 165 
GEM 2.01 1.93 81 TTC14 1.53 1.52 166 
PPFIBP1 1.73 2.15 82 IFRD1 1.51 1.54 167 
CREBZF 2.04 1.85 83 DIAPH3 1.54 1.50 168 
GEM 1.92 1.96 84 UBE2CBP 1.50 1.53 169 
DAB2 2.34 1.52 85 
*Fold-change (FC) reflective the expression of (tumorigenic-enriched derivatives)/(parental populations).
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This list of genes was narrowed to focus on candidates that might represent general 
regulators of tumor re-initiation. Such general regulators would be expected to function 
independent of the local micro-environment, and not be restricted to regulating growth 
only in the organ used for selection or to regulating features either only specific to 
primary tumor formation or metastasis (Figure 3.1a). To identify such candidates, this list 
was combined with the set of genes expressed at greater levels in highly metastatic cells 
that had been previously derived from the same parental populations. Comparison of the 
set of genes that displayed greater expression in the TE derivatives (Table 3.1) and in 
lung-metastatic (LM) sub-lines (Table 3.2) that had been previously generated from the 
MDA-231 (Minn et al., 2005) and CN34 (Tavazoie et al., 2008) cell lines revealed eight 
candidate genes that displayed a greater than 1.5-fold increase in expression in all in vivo 







 Figure 3.1: Systematic identification of candidate promoters of tumor re-initiation 
(a) Genes whose expression was greater in tumorigenic-enriched (TE) and lung-
metastatic (LM) in vivo selected derivatives were considered candidate promoters of 
general features of tumor re-initiation. The intersection of features common to TE and 
LM derivatives was hypothesized to exclude factors only specific to growth in the 
primary organ (mammary microenvironment) or only specific to the metastatic cascade 
(lung microenvironment, extravasation, anoikis). (b) Transcriptomic gene expression 
analysis of TE and LM derivatives from the MDA-231 (MDA-TE3, MDA-LM2) and 
CN34 (CN34-TE2, CN34-LM1a) cell lines were compared relative to their parental 
populations. Eight candidate promoter genes passed a relative 1.5-fold increase cutoff 
criteria. Three genes (LAMA4, FOXQ1, and NAP1L3) demonstrated statistical 
significance through subsequent quantitative real-time PCR (qRT-PCR) assessment.   
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Table 3.2: Genes with increased expression (1.5x higher) in lung-metastatic (LM) 









LM1a FC* # 
MMP1 1.97 32.14 1 KCNK1 1.93 2.98 41 
IL13RA2 27.33 3.69 2 DCLK1 2.05 2.78 42 
WDR72 11.32 5.46 3 ZNF503 1.54 3.08 43 
SPANXA1 6.23 10.46 4 SERPINE2 1.92 2.62 44 
SPANXA1 3.09 11.46 5 ZIC2 2.65 1.88 45 
DCLK1 5.38 9.01 6 KIAA0746 2.06 2.39 46 
GYPC 2.42 8.41 7 FBLN1 2.47 1.97 47 
FOXA1 1.88 8.82 8 CTHRC1 2.06 2.31 48 
ALDH3A1 4.17 5.52 9 RAB37 1.71 2.49 49 
GYPC 1.87 6.97 10 LOC401233 2.12 1.97 50 
LOC731895 1.63 7.00 11 LAMA4 2.56 1.51 51 
KISS1 2.21 6.14 12 CCND2 1.59 2.44 52 
INHBB 2.98 5.19 13 LAMA5 2.50 1.52 53 
PLCB1 3.96 3.69 14 COL6A2 2.42 1.51 54 
CADM1 3.10 4.38 15 NQO1 1.55 2.28 55 
SYK 1.84 5.56 16 NR2F1 1.65 2.17 56 
ITGB4 2.63 4.70 17 QPCT 2.31 1.50 57 
ITGB4 2.45 4.74 18 BICD1 2.10 1.71 58 
PHGDH 3.97 3.18 19 ALDH3A2 1.66 2.07 59 
FRMD3 1.65 5.35 20 SHISA3 1.78 1.84 60 
ODZ3 1.86 5.09 21 SLC22A18 1.73 1.85 61 
CTHRC1 2.64 3.85 22 ALDH3A2 1.63 1.88 62 
LOC124220 1.77 4.65 23 NQO1 1.63 1.88 63 
NAP1L3 1.63 4.65 24 ITGA6 1.71 1.76 64 
POU3F2 1.93 4.14 25 FBLN1 1.78 1.69 65 
TENM1 2.32 3.68 26 TGFBI 1.86 1.60 66 
GARNL4 1.67 4.21 27 PPARG 1.55 1.90 67 
TNFRSF19 1.52 4.29 28 TMEM154 1.90 1.51 68 
FSCN1 2.00 3.80 29 FOXQ1 1.63 1.73 69 
KCNK1 1.91 3.53 30 COL6A2 1.58 1.75 70 
AMPH 2.28 3.12 31 COL13A1 1.66 1.66 71 
CHRM3 2.22 3.10 32 LOC642236 1.62 1.70 72 
SLC47A1 2.18 3.11 33 LAMA4 1.75 1.53 73 
IL_1914933 2.91 2.34 34 SLIT2 1.73 1.54 74 
LDOC1 1.91 3.30 35 SOX21 1.53 1.71 75 
PCDH20 2.44 2.76 36 TRAK2 1.59 1.64 76 
SRGN 3.57 1.62 37 RORA 1.64 1.57 77 
BMP2 1.75 3.40 38 PLAG1 1.53 1.61 78 
CHN2 1.63 3.48 39 FLRT2 1.50 1.63 79 
MPP4 1.58 3.39 40   







Table 3.3: Genes with increased expression in tumorigenic-enriched (TE) 
and lung-metastatic (LM) cells relative to their parental populations 










NAP1L3 1.78 4.62 1.63 4.65 1 
SLIT2 1.91 5.76 1.73 1.54 2 
FRMD3 1.76 1.88 1.65 5.35 3 
SRGN 3.54 1.63 3.57 1.62 4 
LAMA4 1.81 4.39 2.56 1.51 5 
TMEM154 3.25 2.22 1.90 1.51 6 
QPCT 2.47 1.79 2.31 1.50 7 
FOXQ1 1.60 2.07 1.63 1.73 8 





Quantitative real-time PCR validation of this set of eight yielded three genes, LAMA4, 
FOXQ1, and NAP1L3, that displayed significantly greater levels of expression in TE and 
LM derivatives from both cell lines relative to their respective parental populations 
(Figure 3.2a-b). LAMA4 encodes the secreted alpha chain isoform protein laminin-α4, an 
ECM component mainly present in basement membranes (Stenzel et al., 2011). FOXQ1 
is a member of the FOX family of transcription factors with roles in development 
(Goering et al., 2008) and cancer progression (Zhang et al., 2011a). NAP1L3 encodes a 
poorly characterized member of the nucleosome assembly protein 1-like (NAP1L) family 








Figure 3.2: TE cells express increased levels of LAMA4, FOXQ1, and NAP1L3–genes 
also expressed at greater levels by highly metastatic cells (a-b) qRT-PCR assessment 
of the mRNA expression levels of LAMA4, FOXQ1, and NAP1L3 by in vivo selected 
derivatives (MDA-TE3, MDA-LM2, CN34-TE2, CN34-LM1a) from the MDA-231 (a) 
and CN34 (b) cell lines relative to their respective parental populations. n = 3 samples per 
group.  *P<0.05, **P<0.01, ***P<0.001 were obtained using one-sided Student’s t-test 
(a-b). All data are represented as mean + or ± S.E.M. 
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LAMA4, FOXQ1, and NAP1L3 promote metastatic efficiency 
Given their increased expression in tumorigenic-enriched and metastatic derivatives, 
LAMA4, FOXQ1, and NAP1L3 represented candidate promoters of primary and 
metastatic tumor re-initiation. As a first step to assess the function of these genes, in vivo 
studies were conducted to determine if these genes regulate the formation of macroscopic 
nodules by highly metastatic cells. Knockdown of LAMA4, FOXQ1, or NAP1L3 in highly 
metastatic MDA-LM2 and CN34-LM1a derivatives significantly decreased metastatic 
colonization of the lungs based on bioluminescence tracking in both the MDA-LM2 and 
CN34-LM1a cell lines (Figure 3.3a-b, Figure 3.4a-c). Consistent with these genes 
promoting the re-initiation of metastatic colonies, histological analysis of lungs from 
these mice revealed significant decreases in the number of macro-metastases that were 
formed upon knockdown of each of these genes (Figure 3.3c-d).  
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Figure 3.3: LAMA4, FOXQ1, and NAP1L3 promote metastatic efficiency 
(a and c) 2x104 MDA-LM2 cells transduced with either a control shRNA or shRNAs 
targeting LAMA4, FOXQ1, or NAP1L3 were inoculated intravenously into 
immunodeficient mice. shRNA-depletion of LAMA4, FOXQ1, and NAP1L3 led to a 
significant reduction in metastasis as demonstrated by bioluminescence measurements 
over 56 days normalized to post-injection signal at day 0 (a). n = 8 (shControl), n = 8 
(shLAMA4_1), n = 7 (shNAP1L3_1), n = 7 (shFOXQ1_1) independent mice. 
Representative vimentin-stained lungs and quantification of the number of macroscopic 
lung nodules on day 56 (c). n = 4 (shControl), n = 5 (shLAMA4_1), n = 4 
(shNAP1L3_1), n = 5 (shFOXQ1_1) independent lungs. (b and d) 5x104 CN34-LM1a 
cells transduced with either a control shRNA, or shRNAs targeting LAMA4, FOXQ1, or 
NAP1L3 were injected intravenously into immunodeficient mice. shRNA-depletion of 
LAMA4, FOXQ1, and NAP1L3 led to a significant reduction in metastasis as 
demonstrated by bioluminescence measurements over 84 days normalized to post-
injection signal at day 0 (b). n = 26 (shControl), n = 6 (shLAMA4_1), n = 5 
(shNAP1L3_1), n = 5 (shFOXQ1_1) independent mice. Representative vimentin-stained 
lungs and quantification of the number of macroscopic lung nodules on day 84 (c). n = 5 
(shControl), n = 3 (shLAMA4_1), n = 3 (shNAP1L3_1), n = 3 (shFOXQ1_1) 
independent lungs. *P<0.05, **P<0.01, ***P<0.001 were obtained using one-sided 
Mann-Whitney test (a-b), or one-sided Student’s t-test (c-d). All data are represented as 












Figure 3.4: Independent shRNA knockdown of LAMA4, FOXQ1, and NAP1L3 leads 
to suppression of metastasis in vivo (a) 1.5x105 CN34-LM1a cells transduced with 
either a control shRNA hairpin or an independent shRNA hairpin targeting LAMA4 were 
inoculated intravenously into immunodeficient mice. shRNA depletion of LAMA4 led to 
a significant reduction in metastasis as measured by bioluminescence imaging on day 25 
normalized to post-injection signal on day 0. n = 4 (shControl), n = 3 (shLAMA4_2) 
independent mice. (b) 5x104 CN34-LM1a cells transduced with either a control shRNA 
hairpin or an independent shRNA hairpin targeting FOXQ1 were inoculated 
intravenously into immunodeficient mice. shRNA depletion of FOXQ1 led to a 
significant reduction in metastasis as measured by bioluminescence imaging on day 84 
normalized to post-injection signal on day 0. n = 4 (shControl), n = 5 (shFOXQ1_2) 
independent mice. (c) 5x104 CN34-LM1a cells transduced with either a control shRNA 
hairpin or an independent shRNA hairpin targeting NAP1L3 were inoculated 
intravenously into immunodeficient mice. shRNA depletion of NAP1L3 led to a 
significant reduction in metastasis as measured by bioluminescence imaging on day 42 
normalized to post-injection signal on day 0. n = 4 independent mice. *P<0.05, 
**P<0.01, were obtained using one-sided Mann-Whitney test (a-c). All data are 







LAMA4 promotes tumor re-initiation in multiple organ microenvironments 
Upon identifying a set of genes (LAMA4, FOXQ1, and NAP1L3) that displayed increased 
expression in cells with enhanced tumorigenic and metastatic potential, one of these 
genes, LAMA4, was chosen for further study. LAMA4 was selected for further 
characterization based on i) its greater fold expression increase observed in in vivo 
selected derivatives compared to FOXQ1 and NAP1L3, and ii) its encoding of a secreted 
ECM protein that could be therapeutically targeted. Consistent with its extracellular role, 
greater levels of laminin-α4 protein were detected in conditioned media obtained from 




Figure 3.5: TE3 cells secrete greater levels of laminin-α4 relative to their parental 
populations 
Anti-laminin-α4 antibody was used to detect endogenous protein in supernatant collected 
from in vitro culture of MDA-parental or MDA-TE3 cells.  
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The increased expression of LAMA4 in in vivo selected derivatives suggested that 
expression of this gene could enhance the tumor re-initiation capacity of parental breast 
cancer populations. Over-expression of LAMA4 in parental populations led to a 
significant increase (4-fold) in the number of tumors formed upon injection of low 
numbers of cells (10 cells per injection) into the mammary fat pads of immunodeficient 
mice (Figure 3.6a). 
Figure 3.6: Over-expression of LAMA4 in parental populations is sufficient to 
promote orthotopic tumor re-initiation 
(a) 1x101 MDA-parental cells transduced with either an empty vector control or LAMA4 
over-expression vector were injected into the mammary fat pads of immunodeficient 
mice. MDA-parental LAMA4-over-expressing cells yielded tumors in 8/32 sites as 
compared to 2/32 sites for MDA-parental empty vector control cells after 10 weeks (left). 
Gross tumor explants (right). n = 32 independent mammary fat pad injections 
(represented as open squares, right). *P<0.05 was obtained using one-sided Fisher’s exact 
test (a). 
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In the context of injecting a high number of cells (5x105 cells per injection), 
overexpression or depletion of LAMA4 did not significantly alter tumor growth, as there 
were no significant differences in tumor size (Figure 3.7a-b), and depletion of LAMA4 





Figure 3.7: Assessment of LAMA4’s regulation of tumor growth upon injection of 
high cell doses (a) 5x105 MDA-parental cells transduced with either an empty vector 
control or LAMA4 over-expression vector were injected into the mammary fat pads of 
immunodeficient mice. There were no significant differences in the size of the tumors 
formed on day 29. n = 8 independent mammary fat pad injections. (b-c) 5x105 MDA-TE3 
cells transduced with either a control shRNA or two independent shRNAs targeting 
LAMA4 were injected into the mammary fat pads of immunodeficient mice. There were 
no significant differences in the size of the tumors formed on day 39 (b). Tumors were 
formed in all cases (c). n = 8 independent mammary fat pad injections. NS is not 
significant based on one-sided Mann-Whitney test (a-b).  
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Over-expression of LAMA4 in parental populations also led to a significant increase in 
metastatic colonization of the lungs upon tail-vein injection of cancer cells (Figure 
3.8a,c), resulting in a significant increase in the number of macroscopic colonies formed 
(Figure 3.8b,d). Taken together, these results demonstrate that over-expression of LAMA4 





Figure 3.8: Over-expression of LAMA4 in parental populations is sufficient to 
promote metastasis 
(a-b) 4x104 MDA-parental cells transduced with an empty vector control or LAMA4 
over-expression vector were inoculated intravenously into immunodeficient mice. Lung 
bioluminescence was measured on day 56 and normalized to post-injection signal at day 
0 (a). n = 7 independent mice. Lungs were harvested on day 56, vimentin stained, and the 
number of macroscopic nodules per lung was counted. Representative vimentin-stained 
lungs on day 56 (b). n = 7 (control), n = 6 (LAMA4oe) independent lungs. (c-d) 5x105 
CN34-parental cells transduced with either an empty vector control or LAMA4 over-
expression vector were inoculated intravenously into immunodeficient mice. Lung 
bioluminescence was measured on day 133 and normalized to post-injection signal at day 
0 (a). n = 7 independent mice. Lungs were harvested on day 133, vimentin-stained, and 
the number of macroscopic nodules per lung section was counted. Representative 
vimentin-stained lungs on day 133 (b). n = 7 independent lungs. *P<0.05, **P<0.01, 
were obtained using one-sided Mann-Whitney test (a,c-d) or one-sided Student’s t-test 
(b). All data are represented as mean + or ± S.E.M. NS, not significant. 
.  
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Next, the role of endogenous LAMA4 in TE derivatives was assessed and revealed that 
depletion of LAMA4 in TE3 cells significantly decreased (shRNA_1, 2.5-fold; shRNA_2, 
2.33-fold) the numbers of tumors formed upon orthotopic injection of limiting numbers 
of cells (10 cells per injection) into the mammary fat pads of immunodeficient mice 
(Figure 3.9a-b). Depletion of LAMA4 in TE3 cells also led to a significant (11-fold) 
decrease in the numbers of macroscopic colonies formed upon ectopic injection into the 
lungs (Figure 3.10a-b). Collectively, these findings reveal that LAMA4 is sufficient to 
enhance the tumor-forming and metastatic potential of parental populations, that 
endogenous expression of LAMA4 promotes tumor re-initiation in multiple organ 
microenvironments, and that the impact of LAMA4 on tumor re-initiation emerges in the 







Figure 3.9: Endogenous expression of LAMA4 by TE derivatives promotes 
orthotopic tumor re-initiation (a) 1x101 MDA-TE3 cells transduced with either a 
control shRNA or an shRNA targeting LAMA4 were injected into the mammary fat pads 
of immunodeficient mice. MDA-TE3 shControl cells yielded tumors in 15/24 sites as 
compared to 6/24 sites for MDA-TE3 shLAMA4_1 cells after 10 weeks (left). Gross 
tumor explants (right). n = 24 independent mammary fat pad injections (represented as 
open squares, right). (b) 1x101 MDA-TE3 cells transduced with either a control shRNA 
or an independent shRNA targeting LAMA4 were injected into the mammary fat pads of 
immunodeficient mice. MDA-TE3 shControl cells yielded tumors in 14/24 sites as 
compared to 6/24 sites for MDA-TE3 shLAMA4_2 after 10 weeks (left). n = 24 
independent mammary fat pad injections (represented as open squares, right). *P<0.05 




Figure 3.10: Endogenous expression of LAMA4 by TE derivatives promotes ectopic 
tumor re-initiation (a-b) 1x102 MDA-TE3 cells transduced with either a control shRNA 
or an shRNA targeting LAMA4 were injected directly into the lung parenchyma to assess 
ectopic tumor re-initiation capacity. Lung bioluminescence was measured on day 63 and 
normalized to post-injection signal at day 0 (a). n = 5 independent mice. On day 63 lungs 
were sectioned, vimentin stained, and the number of macroscopic nodules per lung was 
counted (b). n = 5 independent lungs. **P<0.01 was obtained using one-sided Mann-
Whitney test (a) or one-sided Student’s t-test (b). All data are represented as mean + or ± 
S.E.M.  
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LAMA4 promotes the clonal expansion of breast cancer cells in the absence of 
substratum-attachment in vitro 
An important feature of malignant cells is their capacity to proliferate and survive in the 
absence of attachment to an underlying matrix during multiple stages of cancer 
progression (Buchstaller et al., 2012; Grassian et al., 2011; Pavlova et al., 2013)–
conditions that can lead to protracted cell cycle arrest or programmed cell death (Aguirre-
Ghiso, 2007). The cell-autonomous expression of LAMA4 by cancer cells suggested that 
this gene might enable them to proliferate independent of attachment to an underlying 
substratum. In order to test this hypothesis, cancer cells were seeded at clonal density in 
vitro into plates that had been treated with a hydrogel layer that prevents adherence to 
substratum. When TE3 cells were seeded at a clonal density of one cell per well onto 
low-attachment 96-well plates that prevent substratum-attachment (Figure 3.11a), wells 
containing LAMA4-depleted cells contained a smaller number cells after 3 days relative to 




Figure 3.11: LAMA4 promotes the clonal expansion of cancer cells in the absence of 
substratum-attachment in vitro (a) To assess the clonal expansion of cancer cells in the 
absence of substratum-attachment in vitro, single cells were sorted at a clonal density of 
one cell per well into low-attachment 96-well plates and monitored over several days. (b-
c) MDA-TE3 cells transduced with either control shRNA or two independent shRNAs 
targeting LAMA4 were sorted at a clonal density of one cell per well into low-attachment 
96-well plates. The number of cells contained in each well was counted on days 1 and 3. 
MDA-TE3 cells transduced with control shRNA proliferated more extensively than 
MDA-TE3 cells transduced with shRNAs targeting LAMA4 (b). n = 212 (shControl_1), n 
= 219 (shLAMA4_1), n = 224 (shLAMA4_2) independent wells. The number of wells 
containing only one cell compared to the number of wells containing multiple cells for 
each condition was assessed on day 3 (c). n = 189 (shControl_1), n = 196 (shLAMA4_1), 
n = 197 (shLAMA4_2) independent wells. Graph c depicts percent of total. *P<0.05, 
***P<0.001 were obtained using one-sided Mann-Whitney test (b) or one-sided Fisher’s 
exact test (c) based on counts on day 3. 
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Based on these findings, tumorigenic-enriched and highly metastatic derivatives, which 
physiologically express elevated levels of LAMA4 relative to their parental populations, 
would be expected to demonstrate greater clonal expansion in the absence of substratum-
attachment in vitro. When TE3 or LM2 cells were seeded onto low-attachment plates at a 
clonal density of one cell per well, they gave rise to a greater number of cells than their 
parental population (Figure 3.12a). In addition, further examination of the wells seeded 
with single cells after several days revealed that a greater fraction of wells seeded with 
TE3 and LM2 cells contained multiple cells relative to wells that had been seeded with 
the parental population, which had a greater fraction of wells that still contained only one 
cell (Figure 3.12b). This effect was also observed in the LAMA4-dependent experiments, 
in which a smaller fraction of wells containing LAMA4 knockdown cells contained 
multiple cells compared to single cells relative to wells containing control hairpin 




Figure 3.12: Tumorigenic-enriched and metastatic derivatives display enhanced 
clonal expansion in the absence of substratum-attachment in vitro (a-b) MDA-
parental, MDA-TE3, or MDA-LM2 cells were sorted at a clonal density of one cell per 
well into low-attachment 96-well plates. The number of cells contained in each well was 
counted on days 1 and 3. MDA-TE3 and MDA-LM2 cells proliferated more extensively 
than MDA-parental cells (a). n = 152 (parental), n = 163 (TE3), n = 141 (LM2) 
independent wells. The number of wells containing only one cell compared to the number 
of wells containing multiple cells for each condition was assessed on day 3 (b). n = 145 
(parental), n = 156 (TE3), n = 133 (LM2) independent wells. Graph b depicts percent of 
total. *P<0.05, ***P<0.001 were obtained using one-sided Mann-Whitney test (a) or 
one-sided Fisher’s exact test (b) based on counts on day 3.  
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Taken together, these observations suggested that LAMA4 might regulate cell cycle 
dynamics during conditions when cells are detached from substratum. This assay was 
modified to enable quantitative analysis of a larger population of cells maintained at a 
low density (Figure 3.13a) and revealed that LAMA4 depletion in the absence of 
substratum-attachment in vitro increased the fraction of cells in G0/G1 (Figure 3.13b). In 
addition, TE3 and LM2 populations cultured under the same conditions contained a 
smaller fraction of cells in G0/G1 relative to their parental populations (Figure 3.13c). 
Taken together, these findings demonstrate that in the absence of substratum-attachment 
in vitro, LAMA4 represses the fraction of cells in G0/G1 and promotes the clonal 





Figure 3.13: LAMA4 represses the fraction of cells in G0/G1 in the absence of 
substratum-attachment in vitro (a) To assess the cell cycle phase of populations of 
cancer cells at low density in the absence of substratum-attachment, cells were seeded at 
low densities into low-attachment 6-well plates in high viscosity media containing 
methyl-cellulose and later isolated and subject to flow-cytometry and cell cycle analysis. 
(b) MDA-TE3 cells transduced with either control shRNA or an shRNA targeting 
LAMA4 were assessed for cell cycle phase using a flow-cytometer (left). Representative 
DNA content histograms from DAPI staining (right). n = 6 independent samples. (c) 
MDA-parental, MDA-TE3, or MDA-LM2 cells were assessed for cell cycle phase using 
a flow-cytometer (left). Representative DNA content histograms from DAPI staining 
(right). n = 4 independent samples. **P<0.01, ***P<0.001 were obtained using one-
sided Student’s t-test (b-c). All data are represented as mean + or ± S.E.M.  
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LAMA4 promotes metastatic proliferation and incipient micro-metastasis formation 
During metastasis, cancer cells that have detached from the primary tumor subsequently 
arrive in a foreign microenvironment with a distinct ECM composition that is acutely 
devoid of proliferative and survival cues that permit the effective formation of colonies 
(Fidler, 2003, 2011; Giancotti, 2013). In addition, studies have shown that the 
introduction of cancer cells into the intravenous circulation leads to the pulmonary 
seeding of mainly solitary cells that initially lack contact with each other (Shibue and 
Weinberg, 2009). These features represent barriers that can prevent the ability of cancer 
cells to regain proliferative potential and to re-initiate metastatic colonies, and they share 
several similarities with the seeding of single cells in non-attachment conditions in vitro. 
The promotion of clonal expansion by LAMA4 under such in vitro conditions suggested 
that this gene might also regulate the initial proliferation of disseminated cancer cells and 
their subsequent formation of multi-cellular colonies in vivo. To address this, highly 
metastatic LM1a cells transduced with either control hairpins or hairpins targeting 
LAMA4 were injected into the venous circulation of immunodeficient mice. After a 
latency period of several days, the bioluminescence signal from the lungs of mice 
injected with control cells began to increase while the signal from mice injected with 
LAMA4-knockdown cells showed a persistently reduced signal (Figure 3.14a). 
Measurement of cancer cell-derived caspase 3/7 activity through an in vivo reporter at 
several time points during this same period revealed no significant differences between 
the normalized signal from animals injected with control cells relative to those injected 
with LAMA4-knockdown cells (Figure 3.15a), demonstrating that the differences in early 
metastatic outgrowth were unlikely to be secondary to apoptosis. Rather, these 
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observations were consistent with LAMA4 promoting the proliferation and expansion of 
cancer cells that had extravasated into the lungs. Analysis of lungs from these animals 
revealed that the knockdown of LAMA4 in LM1a cells resulted in a significant decrease 
in the fraction of multi-cellular colonies relative to single cells in the lungs of mice 
several days after tail-vein injection (Figure 3.14c), demonstrating that LAMA4 promotes 
the formation of micro-metastases in vivo. Additionally, LAMA4 depletion also reduced 
the percentage of solitary cells that stained positively for the proliferative marker Ki67 
(Figure 3.14d), demonstrating that a greater fraction of solitary LAMA4-knockdown cells 
were not actively proliferating. Further analysis revealed that knockdown of LAMA4 led 
to a decrease in the average size of metastatic colonies formed (Figure 3.14b), consistent 






Figure 3.14: LAMA4 promotes the proliferation of disseminated metastatic cells and 
micro-metastasis formation in vivo (a-d) 3x105 CN34-LM1a cells transduced with 
either control shRNA or an shRNA targeting LAMA4 were injected intravenously into 
immunodeficient mice and lung bioluminescence was measured over time (a). n = 5 
independent mice. On day 6, lungs were harvested, sectioned, and stained with vimentin 
and Ki-67. Upon fluorescence image acquisition using confocal microscopy and software 
analysis, the average size of metastatic colonies was quantified (b; representative 
background-subtracted vimentin stained images, right), the number of solitary single cells 
relative to multi-cellular colonies (micro-metastases) was quantified (c; see panel b for 
representative images. Red closed arrows, micro-metastases. Brown open arrows, solitary 
cells), and the percentage of solitary single cells that stained positively for Ki67 was 
quantified (d; vimentin staining in green. Ki67 staining in red. Arrows depict solitary 
cells). n = 5 independent lungs. Micro-mets is micro-metastases. *P<0.05, ***P<0.001 
were obtained using a one-sided Student’s t-test (a-d). All data are represented as mean + 





Figure 3.15: LAMA4 does not significantly regulate apoptosis at early time points 
during metastatic colonization (a) 3x105 CN34-LM1a cells transduced with either 
control shRNA or an shRNA targeting LAMA4 were injected intravenously into 
immunodeficient mice (see Figure 3.14). In vivo quantification of apoptotic cells was 
monitored by measurement of a luciferase-based caspase-3/7 reporter normalized to 
cancer cell luciferase signal over several days (left). Representative luciferase-based 
caspase-3/7 (non-normalized) bioluminescence signal (right). n = 5 independent mice. NS 
is not significant. P value was obtained using a two-sided Student’s t-test (a). All data are 
represented as mean ± S.E.M. 
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An independent experiment employing the highly metastatic LM2 cell line confirmed 
these observations (Figure 3.16a-d). 
 
 
Figure 3.16: Independent validation of LAMA4’s promotion of disseminated 
metastatic cell proliferation and colony formation in vivo (a-d) 3x105 MDA-LM2 
cells transduced with either control shRNA or two independent shRNAs targeting 
LAMA4 were injected intravenously into immunodeficient mice and lung 
bioluminescence was measured over time (a). n = 6 (shControl), n = 4 (shLAMA4_1), n 
= 4 (shLAMA4_2) independent mice. On day 28 lungs were harvested, sectioned, and 
stained with vimentin and Ki-67. Upon fluorescence image acquisition using confocal 
microscopy and software analysis, the average size of metastatic colonies was quantified 
(b; representative background-subtracted vimentin stained images, right), the number of 
solitary single cells relative to multi-cellular colonies (micro-metastases) was quantified 
(c; see panel b for representative images. Red closed arrows, micro-metastases. Brown 
open arrows, solitary cells), and the percentage of solitary single cells that stained 
positively for Ki67 was quantified (d; vimentin staining in green. Ki67 staining in red. 
Arrows depict solitary cells). n = 4 independent lungs. Micro-mets is micro-metastases. 
*P<0.05, **P<0.01 were obtained using a one-sided Student’s t-test (a-d). All data are 
represented as mean + or ± S.E.M.  
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Collectively, these findings demonstrate that LAMA4 promotes the active proliferation of 
disseminated solitary cells and the formation and expansion of incipient multi-cellular 
micro-metastases in vivo. 
FOXQ1 promotes the expression of LAMA4 
The increased expression of FOXQ1 and NAP1L3 along with LAMA4 in independent in 
vivo selected derivatives suggested that these three genes might be co-expressed in other 
breast cancers. Interrogation of a large set of primary breast tumor samples from The 
Cancer Genome Atlas (TCGA) (n = 988; see Methods) revealed that LAMA4 expression 
was positively correlated with the expression of both FOXQ1 and NAP1L3 (Figure 3.17a-
b). 
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Figure 3.17: LAMA4 expression co-varies with the expression of FOXQ1 and 
NAP1L3 in primary breast tumors (a-b) LAMA4 expression was positively correlated 
with the expression of FOXQ1 and NAP1L3 in a large set of primary breast tumor 
samples. Ranked LAMA4 (x-axis) expression values were plotted against ranked FOXQ1 
(y-axis, green) and NAP1L3 (y-axis, blue) expression values (a). R Spearman correlation 
co-efficient between LAMA4 and FOXQ1 or NAP1L3 (b). n = 988 independent primary 
breast cancer patient samples. ***P<0.001 was obtained using a linear regression (b). 
 74 
The co-variance of LAMA4 with FOXQ1 and NAP1L3 suggested that these genes might 
functionally interact. Experiments revealed that the depletion of FOXQ1 using 
independent hairpins in multiple cell lines decreased LAMA4 levels (Figure 3.18c-d)—
consistent with FOXQ1 being upstream of LAMA4. The depletion of LAMA4, however, 
did not lead to consistent or robust changes in the expression of either FOXQ1 or 
NAP1L3 (Figure 3.18a-b). Additional experiments revealed that depletion of NAP1L3 did 
not consistently affect LAMA4 expression across the different cell lines tested (Figure 
3.18e-f). Collectively, these results demonstrate that LAMA4 expression co-varies with 
FOXQ1 and NAP1L3 in primary human tumors, and that FOXQ1 promotes the 







Figure 3.18: FOXQ1 promotes the expression of LAMA4 (a-b) Relative expression of 
LAMA4, FOXQ1 and NAP1L3 following siRNA knockdown of LAMA4 in LM1as (a; n = 
6) or LM2s (b; n = 6) compared to control siRNA. (c-d) Relative expression of LAMA4 
and FOXQ1 following siRNA knockdown of FOXQ1 in LM1as (c; n = 9) or LM2s (d; n 
= 6) compared to control siRNA (e-f) Relative expression of LAMA4 and NAP1L3 
following siRNA knockdown of NAP1L3 in LM1as (a; n = 12) or LM2s (b; n = 10) 
compared to control siRNA. NS is not significant. *P<0.05, ***P<0.001 were obtained 
using a two-sided one-sample t-test (a-f).  
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Summary of findings in Chapter III 
This chapter describes a systematic approach to identify genes that promote tumor re-
initiation through molecular characterization of tumorigenic-enriched derivatives. 
Transcriptomic profiling was used to identify genes that were differentially expressed 
between TE cells and their parental populations. Many of these genes were also found to 
be upregulated in highly metastatic cells that had been previously derived from the same 
parental populations. Three genes (LAMA4, FOXQ1, and NAP1L3) demonstrated greater 
expression in tumorigenic-enriched and metastatic derivatives relative to their parental 
populations. Each of these genes promoted metastatic efficiency in vivo, and one of these 
genes, LAMA4, was selected for further study and characterization. Functional studies 
revealed LAMA4 to be a robust promoter of both tumor re-initiation and metastasis. Over-
expression of LAMA4 in parental populations was sufficient to enhance their tumor re-
initiating and metastatic capacity, while endogenous expression of LAMA4 by 
tumorigenic-enriched cells promoted their capacity to re-initiate tumors in multiple 
microenvironments. Further characterization of the phenotypes regulated by LAMA4 
revealed that it promotes disseminated metastatic cell proliferation and colonization in 
vivo, and in conditions of non-attachment to substratum in vitro, LAMA4 decreases the 
fraction of cells in G0/G1 and promotes the clonal expansion of cancer cells into multi-
cellular units. The identification of LAMA4 as a gene that promotes primary and 
metastatic tumor re-initiation in multiple micro-environments suggests its importance in 
human breast cancer biology, and the following chapter provides clinical evidence to 
further support the relevance of this gene (Chapter IV).  
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CHAPTER IV 
THE CLINICAL RELEVANCE OF THESE FINDINGS 
TO BREAST CANCER 
 
This chapter presents clinical data to support the role of LAMA4 in breast cancer 
progression. Multiple clinical datasets were examined to assess the association of LAMA4 
with early breast cancer progression and clinical relapse. 
 
Increased expression of LAMA4 marks early breast cancer progression 
Based on the increased expression of LAMA4 by tumorigenic-enriched derivatives and its 
sufficiency in promoting tumor re-initiation in vivo, the role of LAMA4 in human clinical 
samples was evaluated. As breast cancers transition from the pre-malignant stage (DCIS) 
to the malignant stage (IDC), cancer cells acquire the ability to proliferate and survive in 
the absence of, or with the proper engagement to, proteins in the ECM as they pass 
through the basement membrane and enter into the surrounding stromal 
microenvironment (Espina and Liotta, 2011). The role of LAMA4 in driving the 
expansion of cancer cells in the settings of non-attachment in vitro, and in multiple 
microenvironments in vivo, suggested that expression of LAMA4 might be increased 
during the transition from pre-malignancy to malignancy in breast cancer. The ideal 
dataset would be one wherein malignant carcinoma cells and pre-malignant cells were 
specifically isolated and separated from the surrounding tissue from the same patient’s 
breast cancer lesion and molecularly interrogated. Multiple datasets (Lee et al., 2012; Ma 
et al., 2009; Ma et al., 2003; Schuetz et al., 2006) of laser capture micro-dissected breast 
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cancer tissues from pre-malignant (DCIS) or malignant (IDC) areas of disease obtained 
from independent patients that had been subjected to transcriptomic microarray analysis 
(Figure 4.1a, see Methods) were identified. Examination of these datasets revealed that 
within the same patients, LAMA4 expression was significantly increased in malignant 
breast cancer cells relative to nearby pre-malignant cancer cells (Figure 4.1b-e; P<0.0001 
for combined datasets). These findings are consistent with the increased expression of 
LAMA4 in populations of cells enriched for tumor-forming potential and support 





Figure 4.1: Increased expression of LAMA4 marks early breast cancer progression 
(a-e) LAMA4 mRNA expression was assessed in multiple gene expression datasets (see 
Methods) from laser capture micro-dissected pre-malignant or malignant human breast 
cancer tissue isolated from individual patients (a). DCIS is ductal carcinoma in situ. IDC 
is intra-ductal carcinoma. BM is basement membrane. Schuetz 2006 (b; n = 9), Lee 2012 
(c; n = 9), Ma 2003 and 2009 (d; n = 26), Lee/Ma/Schuetz (e; n = 44). n is the number of 
independent paired DCIS and IDC patient samples. P values were obtained using a one-
sided paired t-test (b-e).  
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Increased expression of LAMA4 is associated with poor relapse-free survival 
In addition to being associated with early breast cancer progression, the functional 
experiments demonstrating the role of LAMA4 in tumor re-initiation suggested that this 
gene might also be associated with primary or metastatic relapse. Analysis of multiple 
independent datasets (Desmedt et al., 2007; Hatzis et al., 2011;  de e  e   2002; 
Wang et al., 2005) revealed that when patients with ER-negative breast cancer were 
stratified into those whose tumors expressed high or low levels of LAMA4, patients 
whose tumors expressed high levels of LAMA4 had significantly reduced relapse-free 
survival relative to patients whose tumors expressed low levels of LAMA4 (Figure 4.2a-d, 
P<0.0005 for combined datasets). Furthermore, tumors from patients that relapsed 
expressed higher levels of LAMA4 independent of stratification (Figure 4.2f) and 
increased expression of LAMA4 was also associated with shorter overall survival in an 





Figure 4.2: Increased expression of LAMA4 is correlated with clinical relapse 
(a-d) Kaplan-Meier curves depicting relapse-free survival of patients with ER-negative 
breast cancer as a function of their primary tumor’s expression of LAMA4. Patient’s 
whose tumor’s mRNA expression of LAMA4 was greater or lower than the median for the 
population were classified as either LAMA4 High or LAMA4 Low. Wang (a, n = 77), 
Hatzis (b, n = 217), Desmedt/NKI  (c, n = 133), Wang/Hatzis/Desmedt/NKI (d; n = 427). 
n is the number of independent patient samples. ER- is ER-negative. (e) Kaplan-Meier 
curve depicting overall survival of patients with ER-negative breast cancer as a function 
of their primary tumor’s expression of LAMA4. Patient’s whose tumor’s mRNA 
expression of LAMA4 was greater or lower than the median for the population were 
classified as either LAMA4 High or LAMA4 Low. n = 175 independent patient samples. 
ER- is ER-negative. (f) The expression of LAMA4 in primary tumors from ER-negative 
patients that relapsed or did not relapse in the combined Wang/Hatzis/Desmedt/NKI 
dataset was compared. n = 427. ER- is ER-negative. P values were obtained using a one-
sided Mantel-Cox test (a-e), or a one-tailed Mann-Whitney test (f). 
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Summary of findings from Chapter IV 
This chapter presents evidence from clinical samples that support the role of LAMA4 in 
human breast cancer progression. In early breast cancer lesions, malignant breast cancer 
cells express higher levels of LAMA4 relative to adjacent pre-malignant breast cancer 
cells obtained from matched patient samples. These findings support the role of LAMA4 
in early breast cancer progression. The role of LAMA4 in breast cancer relapse was also 
assessed. In patients with ER-negative breast cancer, those patients whose primary 
tumors expressed high levels of LAMA4 succumbed to relapse earlier than patients whose 




SUMMARY AND PERSPECTIVES 
 
Overall summary 
A molecular and cellular understanding of the features that govern tumor-forming 
potential is of great interest to the scientific and biomedical communities (Williams et al., 
2013). This thesis describes a strategy to elucidate the genes and cellular biology that 
govern tumor re-initiation by the application of an unbiased approach to select for 
populations of cells with enhanced tumorigenic capacity. Tumorigenic-enriched (TE) 
populations derived through in vivo selection demonstrated enhanced tumor re-initiation 
capacity in orthotopic as well as ectopic contexts. Transcriptomic profiling revealed a set 
of genes (LAMA4, FOXQ1, and NAP1L3) for which expression levels were increased in 
TE cells relative to their parental populations. These genes were also found to be 
expressed at greater levels by highly metastatic cells, and each of these genes promotes 
metastatic efficiency in vivo. Characterization of one of these genes, LAMA4, revealed it 
to be sufficient to promote the enhancement of both the tumorigenic and metastatic 
potential of breast cancer populations. Endogenous expression of LAMA4 by TE cells 
promoted tumor re-initiation in multiple organ microenvironments. Importantly, 
LAMA4’s regulation of tumor re-initiation emerged in the context of limiting cell 
numbers, a situation that mirrors the pathophysiological progression of human cancers. 
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The ability of cancer cells to survive and to proliferate in the absence of attachment to an 
underlying substrate throughout multiple stages of cancer progression (Pavlova et al., 
2013) led to the hypothesis that cancer-derived LAMA4 could enhance the clonal 
expansion of cancer cells in the absence of substratum-attachment in vitro, and during 
metastatic colonization in vivo, when solitary cells are exposed to a foreign micro-
environment that may lack requisite extracellular cues (Aguirre-Ghiso, 2007; Giancotti, 
2013). In vivo experiments revealed that LAMA4 promotes the fraction of solitary 
disseminated metastatic cells that are proliferating during the initial phase of metastatic 
colonization and enhances the relative numbers and sizes of incipient micro-metastases 
that are generated. Based on this model, the shifting of cells from a resting, non-
proliferative state to a proliferative state would yield a greater number of metastases that 
are re-initiated, while the continued proliferation of cells expressing LAMA4 would 
increase the size of micro-metastases that are formed. Consistent with this, in conditions 
of non-attachment to substratum in vitro that model this process, LAMA4 decreased the 
fraction of cells in G0/G1 and promoted the clonal expansion of cancer cells into multi-
cellular units. 
 
The final phase of this study presents clinical data that support the role of LAMA4 in 
multiple stages of human breast cancer progression. In early breast lesions, malignant 
cancer cells express greater levels of LAMA4 relative to adjacent pre-malignant cancer 
cells obtained from matched patient samples. In addition, increased LAMA4 expression in 
ER-negative human tumors was found to be associated with reduced relapse-free 
survival. Collectively, this thesis describes the application of an unbiased approach to 
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select for populations of cells with enhanced tumorigenic capacity, whose 
characterization led to the identification of a molecular determinant, LAMA4, that 
promotes tumor re-initiation in multiple microenvironments and for which increased 







Illustration 5.1: In vivo selection for tumorigenic-enriched cells uncovers LAMA4 as 
a promoter of tumor re-initiation in breast cancer 
Schematic depicting in vivo selection for tumorigenic-enriched cells, which demonstrated 
enhanced tumor re-initiation capacity and increased expression of LAMA4, FOXQ1, and 
NAP1L3 relative to their parental populations (left). Model depicting LAMA4 promotion 
of proliferation and multi-cellular colony formation in the metastatic niche (right). 
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Derivation and characterization of tumorigenic-enriched populations 
This study describes the derivation of populations of cells with enhanced tumor-forming 
capacity from multiple breast cancer cell lines using in vivo selection. Tumorigenic-
enriched populations derived through this method could be propagated in vitro, 
demonstrated enhanced tumor re-initiation capacity in the primary and metastatic 
microenvironment, and surprisingly did not demonstrate enhancement of multiple in vitro 
phenotypes thought to be associated with increased tumorigenic potential. These results 
reveal several important insights into the underlying biology of cell populations with 
enhanced tumorigenic capacity. 
 
The enhanced capacity of tumorigenic-enriched derivatives to give rise to tumors despite 
being propagated in vitro reveals that their enhancement is not a transient phenotype that 
is lost with passage. The further characterization of tumorigenic-enriched populations 
using cellular, molecular, and biochemical techniques requiring large numbers of cells 
was significantly aided by the ability to propagate and expand these populations in vitro. 
Many other methods that have been used to study highly tumorigenic populations involve 
the isolation of small subsets of cells and as a result often have technical limitations that 
can prevent the application of certain experimental techniques (for example, biochemistry 
typically requires hundreds of thousands or millions of cells) (Gedye and Ailles, 2013). 
The derivation of highly tumorigenic cells from breast cancer cell lines using in vivo 
selection represents a methodological advance that may further the understanding of the 
biological basis for tumorigenicity. In addition, the success of this approach in multiple 
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breast cancer cell lines supports its potential to derive populations of cells with enhanced 
tumor-forming capacity from other cancers. 
 
While it is thought that primary tumorigenic capacity is also associated with enhanced 
metastatic capacity, this question has not been fully explored (Magee et al., 2012; 
Vanharanta and Massague, 2013). This study reveals that in vivo selection for enhanced 
tumor-forming capacity in an orthotopic microenvironment co-selects for i) enhanced 
tumorigenic capacity in the lungs and ii) enhanced metastatic capacity to the liver. The 
enhanced capacity of tumorigenic-enriched derivatives to generate tumors in multiple 
metastatic organ microenvironments relative to their parental populations reveals a 
functional link between primary tumorigenicity and metastatic re-initiation. This link is 
further supported by the finding that multiple genes (LAMA4, FOXQ1, and NAP1L3) are 
commonly expressed at greater levels by populations independently in vivo selected for 
primary tumor re-initiation or metastasis. 
 
Multiple in vitro phenotypes, including proliferation and colony formation under 
adherent conditions, the recruitment of endothelial cells, and attachment to substratum, 
are though to be associated with cancer cell aggressiveness and enhanced tumor-forming 
capacity (Tabaries et al., 2012; Tavazoie et al., 2008; Zhou et al., 2014). The lack of 
enhancement of these multiple in vitro phenotypes by tumorigenic-enriched populations 
demonstrates that selection for these phenotypes is not required for selection of 
populations of cells with enhanced tumorigenic capacity by ER-negative breast cancer 
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cells. In addition, these results underscore the limitations of forming conclusions on in 
vivo properties based on in vitro findings. 
 
Identification of molecular determinants of tumor re-initiation in breast cancer 
LAMA4, FOXQ1, NAP1L3 are a co-varying set of genes expressed at greater levels by 
tumorigenic-enriched and metastatic derivatives 
Transcriptomic profiling revealed a set of genes–LAMA4, FOXQ1, and NAP1L3–to be 
expressed at greater levels by tumorigenic-enriched and metastatic derivatives relative to 
their parental populations. The greater levels of expression of these genes in 
independently derived in vivo selected populations from multiple breast cancer cells lines 
prompted the question of whether they were also co-expressed in other human breast 
cancers. Analysis of a large cohort of primary human breast tumors revealed that LAMA4 
expression co-varied with both FOXQ1 and NAP1L3, suggesting that these genes may 
functionally interact or be co-regulated. Experiments revealed that FOXQ1 promotes the 
expression of LAMA4, suggesting that FOXQ1 acts upstream of LAMA4.  Additional 
experiments revealed no interaction between LAMA4 and NAP1L3. Taken together, these 
results suggest that LAMA4 may be a downstream transcriptional target of FOXQ1. The 
strong correlation in the expression of NAP1L3 and LAMA4 suggests that these genes 
may share a common upstream regulator. 
 
FOXQ1 
FOXQ1 is a member of the FOX family of transcription factors which contain a specific 
DNA-binding motif known as a ‘winged helix’ or ‘forkhead’ domain (Bieller et al., 
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2001). Multiple studies have demonstrated the role of FOXQ1 in hair follicle 
development and in cancer progression (Goering et al., 2008; Zhang et al., 2011a). 
FOXQ1 exerts these effects through the regulation of downstream transcriptional targets, 
although the overlap of these targets in different the phenotypes regulated by FOXQ1 is 
unknown (Abba et al., 2013; Qiao et al., 2011; Sun et al., 2013). This study identifies 
FOXQ1 as a gene whose expression is increased in populations of cells with enhanced 
tumorigenic and metastatic capacity. Depletion of FOXQ1 led to decreased lung-
metastatic colonization as evidenced by a decrease in the numbers of tumor nodules 
formed in the lungs of immunodeficient mice. Co-expression studies revealed a positive 
correlation between FOXQ1 and LAMA4, and functional experiments demonstrated that 
FOXQ1 promotes the expression of LAMA4. Future experiments could give insight into 
whether the promotion of LAMA4 expression by FOXQ1 is through direct transcriptional 
activation. In addition, the epistatic relationship between FOXQ1 and LAMA4 could be 
explored to determine if the phenotypes regulated by FOXQ1 are dependent on the 
expression of LAMA4. Furthermore, the full transcriptional regulatory network impacted 
by FOXQ1 could be assessed in order to identify additional candidate genes that may 
promote tumor re-initiation or metastasis in breast cancer. 
 
NAP1L3 
NAP1L3 is a poorly characterized protein that is a member of a family of nucleosome 
assembly 1-like (NAP1L) proteins that share significant homology to nucleosome 
assembly proteins (NAPs) (Watanabe et al., 1996). NAP1L proteins are thought to be 
involved in chromatin remodeling, and several have been implicated in the nervous 
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system and neuronal differentiation (Cho et al., 2013). Some NAP1L proteins have been 
shown to play roles in cell cycle progression, including NAP1L2, which has been shown 
to impact the cell cycle by regulating the downstream target CDKN1C through an effect 
on histone acetylation (Attia et al., 2011). While NAP1L3 is thought to be expressed 
predominantly in neurons, this study identifies NAP1L3 as a gene expressed by breast 
cancer cells that promotes metastatic efficiency. It would be interesting to determine if 
NAP1L3 is also expressed endogenously by mammary epithelial cells, or if this gene is 
only expressed after their oncogenic transformation into cancer cells. 
 
LAMA4 
LAMA4 is a member of a family of laminin genes that encode proteins normally present 
in the extracellular matrix (ECM) (Hynes, 2009; Nelson and Bissell, 2006). The 
extracellular matrix is responsible for the structural integrity of many organs (Ghajar and 
Bissell, 2008). The ECM also provides critical instructive signals that direct normal tissue 
development and homeostasis, as well as cancer (Artacho-Cordon et al., 2012). Laminins 
are composed of distinct heterotrimers with diverse functions (Hamill et al., 2009; 
Scheele et al., 2007). In humans, there are five alpha chain laminins, three beta chain 
laminins, and four gamma chain laminins, and each laminin heterotrimer is composed of 
one alpha chain, one beta chain, and one gamma chain (Domogatskaya et al., 2012). Most 
laminins polymerize to form long continuous networks that lay the foundation for BM 
formation (Moyano et al., 2010). The conformation of most laminin heterotrimers 
exposes the N-terminal of each laminin chain, which can bind to nearby chains to enable 
the polymerization of long sheets (Domogatskaya et al., 2012). During development, the 
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secretion and deposition of laminins into the extracellular matrix lays the foundation for 
other ECM proteins to bind, such as collagens and fibronectins. While laminins are 
secreted as soluble proteins, cross-linking of proteins to the ECM leads to the formation 
of an insoluble matrix. In addition to providing physical anchoring of cells to the ECM, 
laminins also provide critical signaling cues that regulate cell growth, proliferation, and 
survival (DeHahn et al., 2004; Grassian et al., 2011; Stenzel et al., 2011; Wondimu et al., 
2004). Several groups have interrogated the importance of various stromal and cancer-
derived laminins to cancer progression (Kusuma et al., 2012; Mori et al., 2011; Zhou et 
al., 2004). In many of these studies, the roles of various laminins is thought to be 
restricted to their deposition into the BM and ECM, which is thought to enable cancer 
progression in part by allowing cancer cells to anchor to these surfaces in order to survive 
and proliferate (Fujita et al., 2005; Kusuma et al., 2012; Mori et al., 2011; Yurchenco, 
2011). 
 
The function of each distinct laminin heterotrimer can largely be attributed to the identity 
of its α-chain. Laminins generated from almost all α-chains can form long continuous 
networks that lay the foundation for BM formation (Moyano et al., 2010), except for 
chains that lack an N-terminal ‘head’ region that prevents their de novo polymerization, 
such as the chain encoded by LAMA4 (Hamill et al., 2009). Previous studies have 
revealed that LAMA4 requires enzymatic cross-linking in order for it to be incorporated 
into ECM generated in vitro (Ilani et al., 2013). These features raise the possibility that 
laminin-α4 could bind to receptors on cells and lead to signaling in the absence of its 
attachment and cross-linkage to the extracellular matrix. Candidate receptors for laminin-
α4 include integrins, which are known receptors for laminins and have well-described 
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roles in cell proliferation and survival (Miranti and Brugge, 2002; Moreno-Layseca and 
Streuli, 2014). The cell-autonomous expression by cancer cells of this specific laminin 
gene that lacks an anchoring head region provides a potential mechanism for these cells 
to decouple proliferative capacity from the physiologically constrained requirement of 
attachment to an immobile extracellular matrix. 
 
Future studies could use genetic mouse models to further interrogate the importance of 
LAMA4 to tumorigenesis. In order to study its potential role in development, investigators 
have generated LAMA4 knockout mice, which have been found to have deregulated 
angiogenesis (Stenzel et al., 2011; Thyboll et al., 2002) and abnormalities in the 
peripheral nervous system (Wallquist et al., 2005). Further experiments could be 
conducted by crossing mice lacking LAMA4 with mouse models of spontaneous or 
oncogene-driven mammary tumor formation. It could also be beneficial to generate 
inducible or conditional knockout mouse models of LAMA4 in order to study the effects 
of acute loss of LAMA4 just prior to, or during, the onset of tumorigenesis. 
 
Phenotypes regulated by LAMA4 
Organ-independent tumor re-initiation 
While organ-specific factors can be critical determinants of tumorigenic capacity (Joyce 
and Pollard, 2009; Langley and Fidler, 2011; Welm, 2008), the focus of this study was to 
attempt to identify molecules that regulated general features of tumor re-initiation that 
were not dependent on a particular micro-environment. In order to identify such potential 
general regulators, cells that were independently in vivo selected for enhanced 
tumorigenic or metastatic capacity were transcriptomically compared to reveal a set of 
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common genes more highly expressed in these cells relative to their parental populations. 
It was hypothesized that genes within this overlapping set might function independent of 
the organ used for selection and not be restricted to features only relevant to tumorigenic 
capacity in the primary site or to the metastatic cascade. While the ability of some genes 
to modulate tumor re-initiation may be specific to a particular organ microenvironment, 
functional experiments revealed that LAMA4 promotes tumor re-initiation capacity in 
orthotopic as well as ectopic settings. These results are consistent with LAMA4 governing 
a general feature of tumor re-initiation that is independent of a particular 
microenvironment. Enhanced expression of organ selective regulators of colonization by 
subsets of disseminated cells during metastasis would be expected to provide further 




It is thought that cancer cell interaction with, and remodeling of, the local 
microenvironment during multiple stages of cancer progression (Chou et al., 2013; Gao et 
al., 2012; Kessenbrock et al., 2010; Peduto et al., 2006; Zhang et al., 2013b) can enable 
cells to resume cell division and expand into colonies when they lack important 
extracellular cues (Aguirre-Ghiso, 2007; Giancotti, 2013). An unfavorable 
microenvironment that does not allow for optimum interaction of cancer cell with the 
ECM can lead to proliferative suppression (Goss and Chambers, 2010) or cellular 
quiescence, a period of protracted G0/G1 arrest (Agami and Bernards, 2002; Aguirre-
Ghiso, 2007). The findings that the cell-autonomous expression of LAMA4 promotes the 
proliferation of cells in the absence of substratum-attachment in vitro and during incipient 
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metastatic outgrowth in vivo suggests that LAMA4 antagonizes the suppressive effects 
that these contexts can have on proliferative potential. 
 
Implications of this study to human breast cancer 
Therapeutic applications 
The identification of LAMA4 as a functional promoter of tumor re-initiation in multiple 
ER-negative breast cancer cell lines reveals a candidate target for therapeutic 
intervention. Functional blocking of the secreted LAMA4 protein product could 
potentially suppress the outgrowth of disseminated metastatic cells or prevent the re-
activation of disseminated solitary cells that have not yet gained the capacity to re-
activate proliferative growth. Blocking antibodies against LAMA4 could be generated by 
immunizing mice with laminin-α4 protein and screening for monoclonal antibodies that 
demonstrates a phenotypic response. This study’s identification of LAMA4 as a potential 
therapeutic target in ER-negative breast cancer has important implications for patients 
diagnosed with ER-negative subtypes, an aggressive subset of breast cancers that are 
refractory to treatment with multiple anti-estrogenic therapies (Ali and Coombes, 2002; 
Andre and Pusztai, 2006). 
 
Primary and Metastatic Relapse 
While aggressive cancers can lead to rapid death due to metastatic burden to multiple 
organs, relapse of primary or metastatic disease can occur even after the surgical 
resection of the primary tumor and without any evidence of metastases (Giancotti, 2013). 
Such relapse is thought to be the result of small numbers of residual cells that escape 
treatment which subsequently re-activate proliferative potential in an inhospitable 
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microenvironment after varying periods of time (Aguirre-Ghiso, 2007; Bragado et al., 
2013; Ghajar et al., 2013; Goss and Chambers, 2010; Vanharanta and Massague, 2013). 
The functional experiments from this study that demonstrate the role of LAMA4 in the re-
initiation of tumors in the primary and metastatic site suggested its expression in clinical 
samples might correlate with primary and metastatic relapse. In patients with ER-
negative breast cancer, those patients whose primary tumors expressed higher levels of 
LAMA4 were more likely to suffer from relapse relative to those patients whose tumors 
expressed low levels of LAMA4. The correlation of LAMA4 with primary and metastatic 
relapse suggests its potential as a predictive marker in patients with ER-negative breast 
cancer. Future prospective studies would be needed to establish the prognostic utility of 
LAMA4 expression in patients with ER-negative breast cancer. 
 
Conclusion 
This thesis describes an unbiased system to select and characterize populations of breast 
cancer cells with enhanced tumorigenic potential. Molecular characterization of 
tumorigenic-enriched populations led to the identification of LAMA4 as a gene that 
promotes tumor re-initiation in multiple microenvironments. Characterization of the 
phenotypes governed by LAMA4 revealed it to promote clonal expansion during 
substratum-detachment in vitro and to promote incipient metastatic proliferation and 
colony formation in vivo. Expression of LAMA4 marks the transition from human pre-
malignant to malignant breast cancer, and higher levels of LAMA4 in primary ER-
negative tumors was correlated with poor relapse free-survival. These findings reveal cell 
biological and molecular insights into the processes that underlie tumor re-initiation and 
may have future clinical application in the treatment of breast cancer.
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MATERIALS AND METHODS 
 
Animal studies 
All mouse experiments were conducted in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at The Rockefeller University. 
Six- to twelve-week-old age-matched female NOD scid or NOD scid gamma mice 
obtained from Jackson Labs were used for orthotopic mammary fat pad, experimental 
lung metastasis, ectopic direct-lung, and experimental liver metastasis assays. For 
bioluminescence tracking of cells in vivo, cells were labeled with a triple-fusion reporter 
protein construct (Ponomarev et al., 2004) through retroviral transduction followed by 
FACS to isolate GFP positive transduced cells 48-72 hours later. Non-invasive 
bioluminescence imaging was performed by anesthetizing mice with Isoflurane (Butler 
Schein), retro-orbital injection of D-Luciferin (PerkinElmer) and exposing mice in an 
IVIS ® Lumina II (Caliper Life Science). Quantification of signal was performed with 
Living Image (PerkinElmer) software. In vivo caspase activity was measured by retro-
orbital injections of VivoGloTM Caspase 3/7 Substrate (Z-DEVD-Aminoluciferine 
Sodium Salt) (Promega) and bioluminescence signal was normalized to cancer cell 
luciferase signal (Biserni, 2010). Tumor volume was determined by measuring the small 
(s) and large (l) diameter of tumors using an Electronic Digital Caliper (Fisher Scientific) 




In vivo selection 
To generate tumorigenic-enhanced (TE) derivatives from the MDA-MB-231 and CN34 
human breast cancer cell lines, moderate numbers of parental populations (1×104 MDA-
231-parental or 2×104 CN34-parental cells) were mixed in a 1:1 ratio of PBS and growth-
factor reduced matrigel (356231, BD Biosciences) and injected orthotopically and 
bilaterally into the 2nd and 4th mammary glands of NOD scid mice. Tumors that were 
generated were dissociated into single cells (see below) and propagated in vitro to yield 
1st generation tumorigenic-enhanced (TE1) derivatives. TE1 cells were then subjected to 
another round of in vivo selection by injecting 10-fold less (1×103 MDA-TE1 or 2×103 
CN34-TE1) cells into the mammary fat pads of NOD scid mice, giving rise to a second 
round of tumors that were dissociated into single cells and propagated in vitro to yield 2nd 
generation tumorigenic-enhanced (TE2) derivatives. For the MDA-231 cell line, a third 
round of in vivo selection was performed by injecting MDA-TE2 cells at a dose 10-fold 
less (1×102 cells) into the mammary fat pads of NOD scid mice to give rise to a third 
round of tumors that were then dissociated into single cells and propagated in vitro to 
yield 3rd generation tumorigenic-enhanced (TE3) derivatives. CN34-TE2 cells did not 









For tumor dissociation, tumors were excised, placed in a 6cm tissue-culture dish and 
minced into fine pieces using a scalpel. Cells were collected in a 50mL conical tube by 
washing with PBS using a 25mL pipette and spun down. The pellet was then re-
suspended in 5mL of ACK buffer (Cambrex) and incubated at room temperature for 10 
min for lysis of red blood cells. The mixture was washed with PBS, spun down, and re-
suspended in 10mL of dissociation media comprised of a 1:1 mixture of DMEM:F12 
supplemented with penicillin, streptomycin and fungizone, 1.25mg/mL Collagenase Type 
I (Worthington Biochemical) and 1mg/mL Hyaluronidase (Worthington Biochemical). 
The mixture was placed in shaking incubator at 37°C. Every 30 min, the mixture was 
removed and pipetted up and down with a 25mL pipette for a maximum of 2 hr until the 
mixture had little or no large pieces remaining. After dissociation, PBS was added to the 
mixture and it was spun down for 10 min. The pellet was re-suspended in 7mL of 0.25% 
Trypsin-EDTA (Invitrogen) and placed in shaking incubator at 37°C. After 10 min, 
30mL of 105 FBS-containing DMEM was added to trypsin-neutralize and the solution 
was spun down at 3,000 rpm for 10 min. The pellet, now mainly a fine suspension, was 
re-suspended in 10mL of a 1:1 mixture of DMEM:F12 supplemented with penicillin, 
streptomycin and fungizone, 1mg/mL BSA, 25mM HEPES, and 20,000 Units/L DNase I 
(Worthington Biochemical) and placed in shaking incubator at 37°C. After 10 min, the 
pellet was re-suspended in 10mL of PBS and spun down. The final suspension was 
filtered through a 70µm and then 40µm filter to enrich for a single cell suspension of 
cells. The resulting cells were plated onto adherent tissue-culture plates and grown in 
appropriate media. 
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Orthotopic and ectopic tumor re-initiation assays 
For orthotopic tumor re-initiation assays, cancer cells were mixed in a 1:1 ratio of PBS 
and growth-factor reduced matrigel (356231, BD Biosciences) and injected bilaterally 
into the 2nd and 4th mammary glands of age-matched NOD scid or NOD scid gamma 
mice. After 10 weeks, mice were sacrificed and necropsy was performed. Absence of 
tumor re-initiation was concluded if there was no evidence of tumor growth through 
visual inspection and palpation upon detailed necropsy. Any visual or palpable evidence 
of tumor growth was considered a re-initiating event and counted as positive tumor 
formation. For quantification, n was as the number of independent mammary fad 
injections sites (4 per mouse). For ectopic tumor re-initiation assays, cancer cells were 
mixed in a 1:1 ratio of PBS and growth-factor reduced matrigel (356231, BD 
Biosciences) and injected into the 3rd intercostal space, 3mm deep, directly into the lung 
parenchyma of age-matched NOD scid or NOD scid gamma mice. For ectopic tumor re-
initiation assays, n was as the number of independent mice that were injected or the 
number of independent lungs that were harvested and subjected to histological analysis. 
 
Metastasis assays 
For lung metastasis assays, triple-reporter labeled cells were resuspended in 0.1mL PBS 
and injected using a 27G½ needle (BD) into the lateral tail-vein of age-matched NOD 
scid mice. For liver metastasis assays, triple-reporter labelled cells were resuspended in 
PBS and injected using a 27G½ needle (BD) into the portal circulation of NOD scid 
gamma mice via splenic injection. For both lung and liver metastasis assays, non-invasive 
bioluminescence imaging was performed immediately after cell inoculations using an 
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IVIS ® Lumina II (Caliper Life Science) to assess a baseline level of injected cells on 
day 0. For all metastasis assays, n was as the number of independent mice that were 




MDA-MB-231 (MDA-231) and CN34 breast cancer cell lines were propagated in vitro 
on standard tissue-culture treated plates. MDA-MB-231 cells and their derivatives were 
maintained in DMEM supplemented with 10% FBS, glutamine, pyruvate, penicillin, 
streptomycin and fungizone. CN34 cells and their derivatives were maintained in M199 
supplemented with 2.5% FBS, 10ug/mL insulin, 0.5ug/mL hydrocortisone, 20ng/mL 
EGF, 100ng/mL cholera toxin, glutamine, pyruvate, penicillin, streptomycin and 
fungizone. The MDA-MB-231 and CN34 parental populations and their lung-metastatic 
(LM) derivatives MDA-LM2 and CN34-LM1a have been described in previous 
publications (Minn et al., 2005; Tavazoie et al., 2008). The MDA-MB-231 cell line 
(ATCC) was derived from the pleural effusion of a patient suffering from metastatic 
breast cancer (Cailleau et al., 1978) and the derivation of the MDA-LM2 subpopulation 
through in vivo selection has been described previously (Minn et al., 2005). The CN34 
parental population was formerly isolated from the pleural effusion of a patient with 
metastatic breast cancer treated at MSKCC upon IRB consent as described previously 
(Bos et al., 2009) and the CN34-LM1a derivative was formerly generated through 
inoculation of NOD scid mice with CN34 parental populations and dissociating 
metastatic nodules that had formed in the lungs as described previously (Tavazoie et al., 
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2008). Both cell lines are Estrogen Receptor-negative (ER-negative) (Bos et al., 2009). 
Cells in culture were routinely tested for mycoplasma contamination. For proliferation 
assays in the absence of substratum-attachment, cells were sorted using a FACSAria II 
(Becton Dickinson) at a clonal density of one cell per well into Ultra-Low Attachment 
Surface 96-well plates (Corning) containing EGM-2 media (Lonza). The presence of 
single cells was confirmed after sorting using bright-field microscopy and the number of 
cells contained in each well was counted on subsequent days. For quantification of cell 
proliferation, n was the number of individual wells seeded with single cancer cells. For 
cell cycle analysis in the absence of substratum-attachment, to enable quantitative 
analysis, a greater number of cells were seeded at a low density of 5,000 cells/well into 
Ultra-Low Attachment Surface 6-well plates (Corning) in media containing a 1:1 mixture 
of DMEM supplemented with 10%FBS, glutamine, pyruvate, penicillin, streptomycin 
and fungizone and 2x DMEM mixed 1:1 with 3% methylcellulose stock solution 
(HSC001, R&D). Cells were harvested on day 3, stained with DAPI, analyzed using an 
LSR II (Beckton Dickinson), and cell cycle phase was determined using FlowJo 
(TreeStar) software. For flow cytometry, for immunophenotypic marker analysis, cells 
were incubated in PBS containing mouse anti-human CD44 antibody (APC-conjugated 
clone G44-26: BD Pharmingen) and mouse anti-human CD24 antibody (PE-conjugated 
clone ML5: BD Pharmingen) for 30 minutes on ice. Cells were washed, stained with 
propidium iodide for live-dead exclusion and analyzed using an LSR II (Beckton 




Cell proliferation and colony formation assay 
For cell proliferation assays, 2.5x104 cells were seeded into tissue-culture treated 
adherent 6-well plates (Falcon). Cells were collected through trypsin digestion and 
counted on days 1 and 5. Cell counts were normalized to day 1. For colony formation 
assays, 1x102 cells were seeded in triplicate into tissue-culture treated adherent 10cm 
plates (Falcon). On day 14, plates were washed with PBS, fixed in 6% gluteraldehyde 
(Sigma-Aldrich), stained with 0.5% crystal violet (Sigma-Aldrich), and washed with H20 
to better enable the visualization of colonies that were formed. 
 
Endothelial recruitment assay 
For endothelial recruitment assays, 5x104 cancer cells were seeded overnight onto tissue-
culture treated adherent 24-well plates (Falcon) while human umbilical vein endothelial 
cells (HUVECs; Lonza) grown to 70-80% confluence were serum-starved overnight. The 
next day, HUVECs were labelled with CellTracker RedTM CMTPX (Molecular Probes) 
according to manufacturer’s protocol and 5x104 HUVECs were seeded onto the top layer 
of 3um HTS Fluroblock transwell inserts (BD Falcon) that were fitted to the top of each 
well of 24-well plate. 0.5mL of 0.2% FBS EGM-2 (Lonza) was added to the top and 
bottom of each well. Plates were incubated at 37°C in a tissue-culture incubator for 16 
hours. Upon incubation, the transwell inserts were removed, washed twice with PBS and 
fixed with 4% paraformaldehyde. The inserts were then cut out using a scalpel and 
mounted onto microscopy slides using VECTASHIELD® Mounting Media with DAPI 
(Vector Laboratories). For imaging and quantification, the basal side of each insert was 
imaged via fluorescence using an inverted microscope (Zeiss Axiovert 40 CFL) at 5x and 
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6-9 images per field per insert were collected. Quantification of migrated HUVECs was 
performed using ImageJ (NIH) software(Schneider et al., 2012). 
 
Cell attachment assay 
The cell attachment assay was performed by labelling cancer cells with CellTracker 
RedTM CMTPX (Molecular Probes) according to manufacturer’s protocol and seeding 
1x105 cells per well of a standard tissue culture six-well plate. After 18 hours, each well 
was carefully washed with PBS and the numbers of cells that had attached cells to the 
tissue culture plates was quantified. Quantification was performed by obtaining 
fluorescent images from nine random fields per well, subtracting background signal, and 
measuring the Area Fraction (the fractional area of fluorescence signal that covered each 
field) using ImageJ software (Schneider et al., 2012). 
 
Generation of retrovirus-mediated knockdown cells 
For generation of knockdown cell lines, virus was generated using 293T cells that had 
been grown to 70-80% confluence. Cells were transfected with Lipofectamine ® 2000 in 
antibiotic-free media and 6ug vector A, 12ug vector K, and 12ug of pLKO (with 
blasticidin or puromycin selection marker) shRNA vector. Virus was collected after 48-
72hr, spun down at 2,000 rpm, and filtered using 0.45um nylon mesh. For cell 
transduction, virus was added to cancer cells along with polybrene (Millipore) and cells 
were incubated for 5-6 hrs. After at least 48hr, cells underwent antibiotic selection using 
either 2ug/mL puromycin or 1ug/mL blasticidin. Cells were removed from antibiotic 
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selection once there were no viable cells remaining on a plate that was mock transduced. 










Generation of retrovirus-mediated over-expressing cells 
For generation of over-expression cell lines, virus was generated using 293T cells that 
had been grown to 70-80% confluence. Cells were transfected with Lipofectamine ® 
2000 in antibiotic-free media and 12ug vector gag/pol, 6ug vector VSVG, and 12ug of 
pBABE-puro empty vector or vector containing cloned full-length LAMA4. Virus was 
collected after 48-72hr, spun down at 2,000 rpm, and filtered using 0.45um nylon mesh. 
For cell transduction, virus was added to cancer cells along with polybrene (Millipore) 
for 24 hrs. After at least 48hr, cells underwent antibiotic selection using 2ug/mL 
puromycin. Cells were removed from antibiotic selection once there were no viable cells 
left on a kill plate that was mock transduced. The following primer sequences were used 




LAMA4 Forward: 5’-CCGGCCGAATTCATGGCTTTGAGCTCAGCCTG-3’ 
LAMA4 Reverse: 5’-CCGGCCGTCGACTCAGGCTGCTGGACAGGAGT-3’ 
 
RNA extraction and quantification of mRNA expression 
Total RNA from cells was extracted and purified using the MiRvana (Applied 
BIosystems) or Total RNA Purification Kit (Norgen Biotek) according to manufacturer’s 
protocol. For mRNA quantification, 0.2-2ug of total RNA was subject to reverse 
transcription using the cDNA First-Strand Synthesis Kit (Invitrogen). The resulting 
cDNA was diluted 1:2 or 1:5 and mixed with SYBR ® green PCR Master Mix (Applied 
Biosystems) with primers specific to each gene. Each independent reaction was split into 
quadruplicate wells of a 384-well plate and loaded onto an ABI Prism 7900HT Real-
Time PCR System (Applied Biosystems) to conduct quantitative real-time PCR (qRT-
PCR). Normalization for relative expression of target genes was performed using HPRT, 
GAPDH, or SMAD4 as endogenous controls. The following primer sequences were used: 
 
GAPDH  Forward: 5’- AGCCACATCGCTCAGACAC-3’ 
GAPDH Reverse: 5’- GCCCAATACGACCAAATCC-3’ 
HPRT Forward: 5’- GACCAGTCAACAGGGGACAT-3’ 
HPRT Reverse: 5’- CCTGACCAAGGAAAGCAAAG-3’ 
SMAD4 Forward: 5’- TGGCCCAGGATCAGTAGGT -3’ 
SMAD4 Reverse: 5’- CATCAACACCAATTCCAGCA-3’ 
FOXQ1 Forward: 5’- GCGGACTTTGCACTTTGAA-3’ 
FOXQ1 Reverse: 5’- TTTAAGGCACGTTTGATGGA-3’ 
LAMA4 Forward: 5’- TTCGAACACCAGCTGACAAC-3’ 
LAMA4 Reverse: 5’- AGGTAACCATTGCGCATTTC-3’ 
NAP1L3 Forward: 5’- CTCCCTGGTAGAGTTTGTAGGC-3’ 
NAP1L3 Reverse: 5’- GACAGGTTCCGAGACCATTTT-3’ 
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siRNA knockdown experiments 
For siRNA knockdown experiments, cells were seeded into 6-well plates overnight. The 
following day, cells were washed with PBS, and incubated in Opti-MEM ® (Invitrogen) 
reduced-serum media. Lipofectamine ® 2000 (1:40, Invitrogen) and 50nM of each 
specific siRNA were pre-mixed and incubated for 20 min before being added to the cells. 
After addition of the Lipofectamine/siRNA mixture, the cells were incubated for 5 hours, 
washed with PBS, and normal cell culture media was added. Cells were collected and 
RNA was harvested 24-30hr post-transfection. Control and target gene siRNAs were 
obtained from Dharmacon (Thermo Fisher Scientific). The following siRNA sequences 
with corresponding catalogue numbers were used: 
 
siControl: 5’-UAGCGACUAAACACAUCAA (cat: D-001210-01-05) 
siFOXQ1_1: 5’-ACGAGUACCUCAUGGGCAA (cat: D-008705-01-0005) 
siFOXQ1_2: 5’-UGGCGGAGAUCAACGAGUA (cat: D-008705-02-0005) 
siLAMA4_1: 5’-CUCAGCGGUUGGCAGGCAA (cat: D-011712-19-0005) 
siLAMA4_2: 5’-GAAGGGAGCUCAGCGGUUG (cat: D-011712-20-0005) 
siNAP1L3_1: 5’-GAACAAAUUUCGUGGAUAG (cat: D-011879-01-0005) 







Immunohistochemistry and histology 
Mammary tumors, whole lungs, or livers were excised and fixed through immersion in 
4% para-formaldehyde overnight, and subsequently washed with PBS, 50% Ethanol, 
70% Ethanol prior to being embedded in paraffin. Paraffin blocks were cut into 5µm 
thick sections. For macroscopic tumor quantification, paraffin sections were stained with 
mouse primary antibodies against Vimentin (1:100, clone V9, Vector Laboratories) and 
visualized with Vectastain ABC kit (PK-6012, Vector Laboratories) and DAB 
chromogen (SK-4105, Vector Laboratories); macroscopic nodules were counted on the 
basis of staining for Vimentin. For immunofluorescence, paraffin sections were stained 
with mouse primary antibodies against Vimentin (1:100, Vector Laboratories) and with 
Ki-67 (1:200, ab15580, abcam). Primary antibodies were detected using Alexa Flour dye-
conjugated secondary antibodies (1:200, Invitrogen). Fluorescence was obtained using a 
Leica laser scanning confocal microscope (TCS SP5). For solitary cell/micro-met 
comparisons, unprocessed images were inspected with ImageJ software(Schneider et al., 
2012), and solitary cancer cells and multi-cellular micro-metastatic colonies were 
randomly counted in 10 fields per section or whole sections on the basis of positive 
staining for vimentin. Counts were quantified as percent of the total number of metastatic 
events (solitary cells + micro-metastatic colonies) to normalize for any differences in the 
initial seeding of metastatic cells. To compare colony size, the average colony size was 
quantified using ImageJ software(Schneider et al., 2012). To assess the proliferation of 
solitary cancer cells, the fraction of solitary cancer cells that stained positively for Ki-67 
was quantified. This was achieved by merging unprocessed green (vimentin) and red (Ki-
67) channels using ImageJ software(Schneider et al., 2012); the fraction of vimentin-
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positive solitary cancer cells that were Ki-67-positive was quantified. n was the number 
of independent lungs that were extracted from mice. 
Western blotting 
Conditioned media was prepared by concentrating serum-free supernatant obtained from 
cultured cancer cells incubated for 24hr using 100k cutoff Amicon Ultra (Millipore) 
centrifuge tubes. Protein from conditioned media was separated using SDS–
polyacrylamide gel electrophoresis, transferred to Immobilon-P Transfer Membrane 
(Millipore), and probed with an antibody against human laminin-α4 (1:200; clone 6C3, 
sc-130541, Santa Cruz Biotechnology). Primary antibody was chemiluminescently 
detected using horseradish peroxidase–conjugated secondary antibody (1:10,000), ECL 2 
Western Blotting Substrate (Pierce) and the SRX-101A (Konica Minolta) developer. 
Microarray hybridization and transcriptomic analysis of in vivo selected derivatives 
To identify mRNAs whose levels were increased across tumorigenic-enhanced (TE) and 
lung-metastatic (LM) in vivo selected derivatives as compared to their parental 
populations, total RNA derived from MDA-MB-231 (Parental, TE3 LM2) and CN34 
(Parental, TE2, LM1a) populations was extracted, labeled and hybridized onto Illumina 
HT-12 v3 Expression BeadChip arrays by The Rockefeller University genomics core 
facility. The raw signal intensities for each probe were median-normalized and replicates 
were averaged. Candidate promoters of tumor re-initiation were identified by over-
lapping the set of genes whose expression was at least 1.5x fold-increased in the 
 109 
following conditions: i) MDA-TE3 vs. MDA-Parental, ii) MDA-LM2 vs. MDA-Parental, 
iii) CN34-TE2 vs. CN34-Parental, iv) CN34-LM1a vs. CN34-Parental. Eight candidate 
genes passed these criteria, and three of these genes demonstrated statistically significant 
differences upon independent validation using quantitative real-time PCR (qRT-PCR). 
 
Correlation coefficient analysis 
Ranked expression values for LAMA4, FOXQ1, and NAP1L3 in primary breast tumors 
from 988 patients from The Cancer Genome Atlas (TCGA) Breast Cancer project 
provisional dataset were downloaded from http://www.cBioPortal.org/ and subjected to a 
linear regression analysis. P values were based on Spearman’s coefficient test. 
 
mRNA analysis of micro-dissected patient samples 
For comparison of pre-malignant and malignant breast cancer tissues, the following 
datasets were used: Schuetz 2006 (GSE3893) (Schuetz et al., 2006), Lee 2012 
(GSE41197) (Lee et al., 2012), Ma 2003: (Table 4) (Ma et al., 2003), Ma 2009 
(GSE14548) (Ma et al., 2009). Each dataset included patient-matched laser capture 
micro-dissected epithelial cancer tissue (to restrict the analysis only to cancer cells) from 
regions of pre-malignant (ductal carcinoma in situ) or malignant (invasive ductal 
carcinoma) disease. Probe intensity values for LAMA4 were used to quantify mRNA 
expression levels (multiple probe values were averaged) in each dataset, intra-sample 
normalized, and subject to a paired t-test to determine statistical significance and the 
average fold-change across individual or combined datasets. 
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Clinical Correlation Analysis 
The expression of LAMA4 in ER-negative tumors was assessed in the following datasets: 
Wang (GSE2034) (Wang et al., 2005), Desmedt (GSE7390) (Desmedt et al., 2007), 
Hatzis GSE25066) Hatzis et l., 2011), KI  de e  e   2002  d e e
e e   e  e  e   d e  / /
To  generate  Kaplan-Meier curves, for each  dataset patients e e  ed d   
those  patients whose   expression of  LAMA4 was  higher  LAMA4    e  
LAMA4   than  the  median  value  for  all ER-negative  tumor  e     
dataset. ER-negativity was  assessed from the clinical annotations  ded   e
dataset. Relapse-free  or  overall survival  outcome was censored at 5 e  ed  d 
subjected to  a  one-tailed Mantel-Cox test. For  Affymetrix  chips with e e
only the JetSet (Li et al., 2011) probe (202202_s_at) was used. For     
LAMA4 expression in tumors derived from patients that did, or did  not  e e  e 
combined Wang/Hatzis/Desmedt/NKI dataset, LAMA4 expression values e e e ed
into z-scores within each dataset before being separated into Relapse or e e ee










Throughout all figures: center values represent mean, error bars represent + or ± SEM; 
*P<0.05, **P<0.01, and ***P<0.001 unless otherwise noted. Statistical significance was 
concluded at P<0.05. For animal studies, the investigator was not blinded during group 
allocation during the experiment or when assessing outcome, no statistical method was 
used to predetermine sample size, and the experiments were not randomized. The 
statistical tests used to determine P values are listed in each Figure Legend. Samples 
whose values were greater than two standard deviations from the mean were considered 
outliers and exclude from the analysis. Data analyzed using an unpaired Student’s t-test 
were under the assumption of normality and equal variance unless otherwise specified. 
For non-normal data, analysis was performed using a Mann-Whitney test; normality was 
assessed using a Shapiro-Wilk test. If there was a significant difference in variance, a 




Microarray gene expression data from the parental MDA-MB-231 and CN34 cell lines 
and their respective tumorigenic-enriched (TE) and lung-metastatic (LM) derivatives are 
deposited at GEO under the accession number GSE52629. 
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